Ophthalmology – X-Linked Retinoschisis

What the Disorder Represents

X-linked retinoschisis (XLRS) is an inherited vitreoretinal dystrophy caused by pathogenic variants in the RS1 gene.

It predominantly affects males and is characterized by:

• Bilateral foveal schisis
• Reduced central vision
• Peripheral retinoschisis in many patients
• Characteristic electroretinographic abnormalities
• Risk of vitreous hemorrhage and retinal detachment

The hallmark structural finding is:

Spoke-wheel cystic/schitic separation of the macula, usually without fluorescein leakage.

The Genetic Basis

XLRS is caused by pathogenic variants in:

RS1 on chromosome Xp22.13.

RS1 encodes:

Retinoschisin

a secreted retinal protein important for:

• Cellular adhesion
• Retinal structural organization
• Synaptic integrity

Loss of functional retinoschisin weakens adhesion between retinal cells and promotes:

Splitting within retinal layers.

Important Modern Correction About Pathogenesis

Older descriptions proposed that XLRS was primarily a:

• Müller-cell disorder
• Retinal vascular developmental disorder

Modern evidence instead indicates that the fundamental defect is:

Abnormal retinoschisin-mediated retinal cellular adhesion and signaling.

Müller cells and retinal neurons may participate secondarily, but they are not considered the sole primary cause.

Inheritance Pattern

XLRS is:

X-linked recessive.

It therefore affects almost exclusively:

Males.

Carrier females are usually asymptomatic because they possess a second normal X chromosome, although rare retinal abnormalities can occur with skewed X-inactivation or unusual genetic circumstances.

Family Transmission Pattern

For an affected male:

• All daughters inherit the pathogenic RS1 variant and are typically carriers
• Sons do not inherit the father’s X chromosome

For a carrier female, each pregnancy has approximately:

• 50% chance that a son will be affected
• 50% chance that a daughter will be a carrier

Genetic counseling is therefore important.

When Patients Usually Present

XLRS frequently becomes apparent during:

Childhood, often in the first decade.

Presentation may include:

• Reduced visual acuity
• Strabismus
• Reading difficulty
• Abnormal school vision screening

Severe disease may present in infancy with:

• Nystagmus
• Strabismus
• Vitreous hemorrhage
• Retinal detachment

Typical Visual Acuity

Central visual acuity is often moderately reduced rather than profoundly poor.

Many patients remain in the approximate range of:

20/40–20/100

for years, although severity is highly variable.

Marked early visual loss should raise concern for:

• Macular detachment
• Vitreous hemorrhage
• Retinal detachment
• Advanced macular degeneration

The Classic Macular Appearance

The hallmark fundus appearance is:

Foveal schisis with radial folds or cystic spaces forming a spoke-wheel pattern.

On ophthalmoscopy, the fovea may show:

• Fine radiating striae
• Microcystic appearance
• Reduced foveal reflex

This may be subtle clinically and is much easier to recognize with:

OCT.

Why It Is Called Retinoschisis

“Schisis” means:

Splitting.

In XLRS, the neurosensory retina separates within its retinal layers rather than separating completely from the RPE as occurs in ordinary retinal detachment.

Optical Coherence Tomography

OCT is the most useful structural test.

It typically demonstrates:

• Intraretinal schisis cavities
• Foveal thickening
• Radial cyst-like spaces
• Bridging retinal tissue

The cavities may involve several layers, particularly:

• Inner nuclear layer
• Outer plexiform layer
• Outer nuclear layer
• Occasionally other retinal layers

Important Modern Correction About the Retinal Layer

Older teaching often emphasized splitting primarily in the:

Nerve fiber layer.

Modern OCT demonstrates that macular schisis can involve:

Multiple retinal layers, with the inner nuclear layer being particularly common.

Why This Is Not Ordinary Cystoid Macular Edema

The OCT can resemble severe cystoid macular edema.

However, XLRS schisis represents:

Structural splitting rather than primarily vascular leakage.

This distinction is reflected on fluorescein angiography.

Fluorescein Angiography

One of the most useful diagnostic clues is:

Little or no fluorescein leakage from the foveal cystic spaces.

This helps distinguish XLRS from true cystoid macular edema due to:

• Uveitis
• Diabetes
• Retinal vein occlusion
• Postoperative inflammation

Thus:

Cystic OCT spaces + little FA leakage in a young male = consider XLRS.

Peripheral Retinoschisis

Peripheral schisis develops in approximately:

Half of affected patients, although reported frequencies vary.

It most commonly involves the:

Inferotemporal retina.

It may appear as:

• Elevated transparent retina
• Bullous schisis
• Inner retinal holes
• Abnormal retinal vessels crossing the schisis cavity

Vascular Changes

Retinal vessels traversing the schisis may be:

• Poorly supported
• Sheathed
• Tortuous

Occasionally there may be:

• Peripheral ischemia
• Telangiectatic change
• Neovascularization

Fragile unsupported vessels contribute to the risk of:

Vitreous hemorrhage.

Vitreous Veils

A classic peripheral finding is:

Vitreous veils

consisting of thin residual inner retinal tissue associated with peripheral schisis.

These may accompany:

• Inner-layer breaks
• Abnormal vessels

and can be diagnostically helpful.

Electroretinography

Full-field ERG classically demonstrates an:

Electronegative response

in which the:

• a-wave is relatively preserved
• b-wave is disproportionately reduced

This reflects dysfunction of transmission between photoreceptors and inner retinal bipolar pathways.

Important Modern Correction About ERG

An electronegative ERG is:

Characteristic but not universal.

Not every patient has the classic pattern, particularly:

• Very young patients
• Mild phenotypes
• Advanced retinal degeneration

Therefore a normal or atypical ERG does:

Not completely exclude XLRS.

Why the a-Wave and b-Wave Differ

The a-wave primarily reflects:

Photoreceptor activity.

The b-wave depends more heavily on:

• Bipolar cells
• Müller-cell-associated inner retinal activity

XLRS disproportionately disrupts inner retinal signaling, producing:

A low b-wave relative to the a-wave.

Genetic Testing

Molecular testing for:

RS1 pathogenic variants

is now a central part of diagnosis.

It can:

• Confirm XLRS
• Distinguish it from phenocopies
• Identify carrier females
• Support family counseling
• Determine eligibility for clinical trials

When Genetic Testing Is Particularly Useful

Consider testing in a male with:

• Bilateral foveal schisis
• Electronegative ERG
• Family history of similar disease
• Peripheral schisis

It is also valuable in atypical cases where:

OCT findings alone are not definitive.

Fundus Autofluorescence

FAF may show:

• Altered macular autofluorescence
• Changes corresponding to chronic RPE stress or atrophy

It is supportive but less important diagnostically than:

• OCT
• ERG
• Genetic testing

Visual Fields

Visual field testing may demonstrate:

• Central or paracentral sensitivity loss
• Scotomas corresponding to peripheral schisis
• Field loss from retinal detachment

It is not usually necessary for diagnosis in young children.

How the Disease Changes With Age

During childhood and early adulthood:

• Foveal schisis may remain stable or fluctuate

With increasing age:

• Schisis cavities may partially collapse
• Macular thinning develops
• RPE changes increase
• Outer retinal atrophy may become more prominent

Thus an older patient with genetically confirmed XLRS may have:

Macular atrophy with relatively little visible schisis.

Why Vision Can Worsen Later in Life

Late visual decline is often due not to increasing schisis but to:

• Macular atrophy
• Photoreceptor degeneration
• RPE abnormalities
• Prior retinal detachment
• Recurrent vitreous hemorrhage

Strabismus and Amblyopia

Children may develop:

• Strabismus
• Anisometropia
• Amblyopia

These treatable causes of additional visual loss should not be overlooked simply because an inherited retinal disorder is present.

Refractive Error

Hyperopia has traditionally been described in XLRS, but refractive error is variable.

Patients should receive:

Full appropriate optical correction

to maximize visual development.

Important Diagnostic Alternatives

The differential includes:

• Enhanced S-cone syndrome / Goldmann-Favre phenotype
• Acquired degenerative retinoschisis
• Cystoid macular edema
• Familial exudative vitreoretinopathy
• Retinitis pigmentosa
• Retinal vasculitis
• Wagner syndrome
• Other inherited vitreoretinopathies

XLRS vs Acquired Degenerative Retinoschisis

XLRS

• Young male
• Bilateral
• Foveal schisis characteristic
• RS1 mutation
• Electronegative ERG may occur

Degenerative Retinoschisis

• Usually older adults
• Peripheral retinal splitting
• Typically no characteristic foveal schisis
• Not X-linked

XLRS vs Enhanced S-Cone Syndrome

Enhanced S-cone syndrome may also cause:

• Foveal schisis
• Peripheral retinal degeneration

However, patients commonly have:

• Prominent nyctalopia
• Characteristic pigmentary changes
• Distinctive ERG abnormalities involving enhanced S-cone function
• Autosomal recessive NR2E3 disease

XLRS vs True Cystoid Macular Edema

True CME generally shows:

Fluorescein leakage.

XLRS macular cavities typically show:

Minimal or absent leakage.

This is a classic examination distinction.

The Main Treatment Principle

There is currently:

No approved curative or disease-modifying treatment for XLRS.

Management focuses on:

• Maximizing useful vision
• Treating refractive error and amblyopia
• Reducing schisis in selected patients
• Detecting retinal complications early

Carbonic Anhydrase Inhibitors

Topical:

Dorzolamide

or systemic:

Acetazolamide

may reduce macular schisis cavities in some patients.

The response is variable.

What CAIs Can Achieve

Some patients demonstrate:

• Decreased central retinal thickness
• Smaller schisis cavities
• Modest improvement in visual acuity

Others show:

• Structural improvement without meaningful visual change
• No response
• Recurrence despite continued therapy

Therefore treatment should be assessed using:

Both OCT and visual function.

Why CAIs May Help

The exact mechanism is uncertain but may involve effects on:

• RPE ion transport
• Retinal fluid movement

The treatment does not correct the underlying:

RS1 genetic defect.

Topical vs Oral CAI

Topical dorzolamide is often tried first because systemic therapy has more adverse effects.

Oral acetazolamide may produce:

• Paresthesias
• Fatigue
• Electrolyte disturbances
• Nephrolithiasis
• Metabolic acidosis

Long-term treatment therefore requires appropriate monitoring.

Prophylactic Laser Is Not Recommended

Laser photocoagulation around uncomplicated peripheral schisis has historically been attempted.

Routine prophylactic laser is:

Not recommended.

It can:

• Create retinal breaks
• Increase traction
• Potentially precipitate rhegmatogenous retinal detachment

Observation is preferred unless there is a specific treatable complication.

Vitreous Hemorrhage

Vitreous hemorrhage may result from:

• Rupture of unsupported vessels
• Traction
• Less commonly retinal neovascularization

Many hemorrhages clear spontaneously.

When Vitrectomy Is Needed for Hemorrhage

Pars plana vitrectomy may be considered when hemorrhage is:

• Dense
• Recurrent
• Nonclearing
• Preventing evaluation of the retina

Earlier intervention may be considered in young children because prolonged visual deprivation can cause:

Amblyopia.

Retinal Detachment

Retinal detachment is one of the most important complications.

Mechanisms include:

• Outer retinal breaks
• Inner and outer layer breaks
• Vitreoretinal traction
• Combination of schisis and rhegmatogenous detachment

Why Retinal Detachment Is Technically Difficult

XLRS eyes may have:

• Fragile retina
• Abnormal vitreoretinal adhesion
• Large schisis cavities
• Thin inner retinal layers

These features complicate retinal repair.

Surgical Management of Retinal Detachment

Modern repair commonly uses:

Pars plana vitrectomy with internal tamponade

when significant traction or complex retinal breaks are present.

Additional options may include:

• Laser retinopexy around true breaks
• Gas or silicone oil tamponade
• Scleral buckle in selected configurations

Surgical planning should be individualized by a vitreoretinal surgeon.

Why Not Every Schisis Cavity Needs Surgery

A stable peripheral schisis cavity without:

• Progressive retinal detachment
• Vision-threatening extension
• Significant traction

usually requires:

Observation rather than intervention.

Operating on structurally fragile retina can create more harm than benefit.

Retinal Neovascularization

True neovascularization is uncommon but may occur with peripheral ischemia.

Management may include:

• Laser photocoagulation to ischemic retina
• Anti-VEGF as an adjunct in selected cases

Treatment is directed at the complication rather than the underlying XLRS.

Role of Gene Therapy

Because XLRS results from loss of a secreted retinal protein, it has been an attractive target for:

RS1 gene-replacement therapy.

Human clinical trials using intravitreal gene therapy have demonstrated:

• Biological activity
• Significant inflammatory challenges
• Variable structural and functional benefit

As of current clinical practice:

No RS1 gene therapy is approved for routine treatment.

Why Gene Therapy Remains Challenging

Effective treatment must deliver functional RS1 broadly across the retina while avoiding:

• Intraocular inflammation
• Immune responses to viral vectors
• Retinal toxicity

Research continues.

Low-Vision Support

Patients with significant central visual impairment may benefit from:

• Magnification
• Electronic reading aids
• Classroom accommodations
• High-contrast materials
• Low-vision rehabilitation

Children should receive appropriate educational support early.

Activity and Eye Protection

There is no universal evidence-based prohibition against ordinary physical activity.

However, because vitreous hemorrhage and retinal detachment can occur:

• Significant ocular trauma should be avoided
• Protective eyewear is reasonable during high-risk activities

Restrictions should be individualized rather than imposing blanket sports bans.

Follow-Up Strategy

Patients require regular lifelong retinal follow-up.

Monitor:

• Visual acuity
• Refraction
• Strabismus/amblyopia
• Macular OCT
• Peripheral retina
• Vitreous hemorrhage
• Retinal detachment

The interval depends on:

• Age
• Severity
• Peripheral schisis
• Previous complications

Symptoms Requiring Urgent Reassessment

Patients and families should seek prompt retinal evaluation for:

• Sudden increase in floaters
• Photopsias
• Curtain or field defect
• Sudden reduction in vision

These can indicate:

• Vitreous hemorrhage
• Retinal tear
• Retinal detachment

Expected Long-Term Course

XLRS usually progresses:

Slowly.

Many patients retain useful central vision through childhood and early adulthood.

Later deterioration can occur from:

• Macular atrophy
• Retinal detachment
• Recurrent hemorrhage
• Outer retinal degeneration

The course varies considerably even among members of the same family.

Major Causes of Permanent Visual Loss

These include:

• Macular atrophy
• Retinal detachment
• Recurrent vitreous hemorrhage
• Amblyopia
• Advanced outer retinal degeneration

The schisis cavities themselves do not always correlate directly with visual acuity.

High-Yield Takeaways

• X-linked retinoschisis is an X-linked recessive inherited retinal dystrophy caused by pathogenic variants in RS1, which encodes retinoschisin.
• It affects almost exclusively males, usually presenting during childhood with reduced central vision.
• The hallmark is bilateral foveal schisis with a spoke-wheel appearance.
• Peripheral schisis occurs in roughly half of patients, classically inferotemporally.
• Modern OCT shows schisis involving multiple retinal layers, particularly the inner nuclear layer; it is not confined to the nerve fiber layer.
• The macular cavities resemble CME on OCT but typically show little or no fluorescein leakage.
• A classic ERG demonstrates an electronegative response with disproportionately reduced b-wave, but this is not present in every patient.
• RS1 genetic testing is now a central diagnostic tool and enables carrier testing and genetic counseling.
• Older patients may show macular atrophy with collapse of previously obvious schisis cavities.
• Treat refractive error, strabismus, and amblyopia aggressively because these can add preventable visual loss.
• Topical dorzolamide or oral acetazolamide may reduce macular schisis in selected patients, although visual benefit is variable.
• Routine prophylactic laser around peripheral schisis is not recommended because it may increase retinal complications.
• Vitreous hemorrhage often clears spontaneously, but persistent or dense hemorrhage may require vitrectomy, especially during the amblyogenic years.
• Retinal detachment may result from retinal breaks and vitreoretinal traction and frequently requires pars plana vitrectomy with individualized tamponade.
• True retinal neovascularization is uncommon; when present, treatment targets the ischemic complication rather than the inherited schisis itself.
• No approved curative or RS1 gene-replacement therapy currently exists, although gene therapy remains under investigation.
• Sudden floaters, photopsias, field loss, or abrupt visual decline require urgent examination for vitreous hemorrhage or retinal detachment.
• The disease is usually slowly progressive, with late visual decline often resulting from macular atrophy rather than simply enlargement of the schisis cavities.
• Lifelong retinal surveillance and genetic counseling are essential.

High-Yield Takeaways

Ophthalmology – Wyburn–Mason Syndrome

What the Disorder Represents

Wyburn–Mason syndrome is a rare congenital, usually sporadic neuro-oculo-cutaneous vascular malformation syndrome characterized by arteriovenous malformations (AVMs) involving the retina and, in many affected patients, the ipsilateral brain, orbit, or facial structures.

It is also called:

• Bonnet–Dechaume–Blanc syndrome
• Retinocephalic vascular malformation syndrome
• Racemose hemangiomatosis

The characteristic ocular lesion is a:

Retinal arteriovenous malformation with direct communication between arteries and veins.

An Important Modern Distinction

An isolated retinal AVM is not automatically equivalent to Wyburn–Mason syndrome.

The term Wyburn–Mason syndrome is most appropriately used when retinal AVMs occur as part of a broader ipsilateral vascular malformation involving structures such as:

• Brain
• Orbit
• Face
• Maxillofacial tissues

A patient with a retinal racemose AVM should therefore be evaluated for:

Associated intracranial and orbital vascular malformations.

How the Vascular Malformation Develops

AVMs arise from abnormal embryologic vascular development.

Instead of normal progression:

Artery → arteriole → capillary bed → venule → vein

there is an abnormal direct connection between:

Arterial and venous circulations.

This creates a high-flow vascular shunt.

Why the Vessels Become So Dilated

Without the resistance of a normal capillary bed:

• Arterial blood enters veins at high pressure
• Feeding arteries enlarge
• Draining veins become dilated and tortuous
• High-flow shunting may develop

The retinal lesion therefore often looks like:

A striking tangle of enormously dilated arteries and veins with direct arteriovenous communication.

Genetic Pattern

Wyburn–Mason syndrome is generally:

Sporadic and nonhereditary.

No consistent Mendelian inheritance pattern has been established.

Routine family screening is therefore usually unnecessary unless another inherited vascular disorder is suspected.

Typical Laterality

The disorder is usually:

Unilateral

and associated CNS or facial vascular malformations tend to occur on the:

Same side as the retinal lesion.

Bilateral retinal involvement is unusual.

When It Becomes Apparent

The malformation is congenital, but diagnosis can occur at almost any age.

Some patients are detected:

• Incidentally during routine eye examination
• During evaluation for reduced vision
• After neurologic symptoms
• Following intracranial hemorrhage

Thus congenital disease does not necessarily mean:

Childhood presentation.

What Patients May Notice

Many patients with retinal AVMs remain asymptomatic.

Possible ocular symptoms include:

• Reduced visual acuity
• Visual-field loss
• Diplopia
• Eye redness
• Floaters
• Proptosis
• Ocular discomfort

Visual symptoms depend mainly on:

• Macular involvement
• Optic nerve involvement
• Vascular complications

Neurologic Symptoms

Associated intracranial AVMs may produce:

• Headache
• Seizures
• Focal weakness
• Sensory deficits
• Cranial nerve palsies
• Visual-field loss
• Altered consciousness

The most serious presentation is:

Intracranial hemorrhage.

Craniofacial Manifestations

Associated vascular malformations may involve:

• Orbit
• Conjunctiva
• Eyelids
• Face
• Maxilla
• Mandible
• Oral cavity

Possible findings include:

• Facial vascular lesions
• Dilated conjunctival vessels
• Epistaxis
• Oral bleeding
• Proptosis

Significant oral or maxillofacial AVMs can produce severe hemorrhage after:

Dental extraction or surgery.

The Classic Retinal Appearance

Fundus examination may show:

• Markedly dilated retinal arteries
• Markedly dilated retinal veins
• Tortuous vessels
• Direct artery-to-vein communications
• Little or no intervening normal capillary network

The vessels may involve:

• A limited retinal sector
• An entire retinal quadrant
• Much of the retina
• Optic nerve head

Traditional Retinal AVM Classification

The classic Archer classification divides retinal AVMs into three groups.

Group 1 – Mild AV Communication

There is an abnormal vascular network between artery and vein with a relatively recognizable intervening capillary component.

These lesions are generally:

• Less extensive
• Less visually destructive
• Less strongly associated with CNS AVMs

They may sometimes represent an isolated retinal vascular malformation rather than full Wyburn–Mason syndrome.

Group 2 – Direct Arteriovenous Communication

There is:

Direct communication between a retinal artery and vein without a normal intervening capillary bed.

The involved vessels are:

• Enlarged
• Tortuous
• High-flow

This pattern has a stronger association with:

Ipsilateral intracranial AVMs.

Group 3 – Extensive Racemose Malformation

This is the most dramatic phenotype.

Features include:

• Massive dilation of arteries and veins
• Numerous direct AV communications
• Extensive retinal involvement
• Difficulty distinguishing artery from vein

These eyes carry the greatest risk of:

• Poor vision
• Vascular occlusion
• Glaucoma
• Optic nerve damage

They are also more strongly associated with:

CNS involvement.

Optic Nerve Involvement

AVMs may involve or surround the optic disc.

Possible consequences include:

• Optic disc edema
• Optic atrophy
• Reduced color vision
• RAPD when asymmetric
• Visual-field loss

Vision may be limited from birth or deteriorate later because of vascular complications.

Why Vision May Be Poor Even Without Hemorrhage

Reduced vision can result from:

• Macular involvement by anomalous vessels
• Chronic retinal ischemia
• Optic nerve dysfunction
• Amblyopia in childhood
• Vascular occlusion
• Secondary glaucoma

Therefore visual loss is not necessarily due to bleeding.

Fluorescein Angiography

FA classically demonstrates:

Very rapid arteriovenous transit through the abnormal communications.

Typical findings include:

• Early arterial filling
• Almost immediate filling of draining veins
• Enlarged feeding and draining vessels

Unlike retinal neovascularization, uncomplicated AVMs generally show:

Little or no leakage.

Why the Lack of Leakage Matters

The absence of substantial fluorescein leakage helps distinguish congenital AVMs from:

• Proliferative diabetic retinopathy
• Retinal neovascularization
• Vasoproliferative tumors

Leakage may occur if secondary vascular complications develop.

Optical Coherence Tomography

OCT can demonstrate:

• Enlarged intraretinal vascular channels
• Shadowing beneath abnormal vessels
• Distortion of retinal layers
• Macular edema if complications develop

OCT is most useful when the AVM approaches:

The macula or optic nerve.

OCT Angiography

OCTA can noninvasively demonstrate:

• Abnormal high-flow retinal vessels
• Direct arteriovenous channels
• Distortion of superficial and deep vascular plexuses

It is useful for structural vascular mapping but does not replace angiographic or neurovascular imaging when associated cerebral AVMs are suspected.

Why Brain Imaging Is Essential

A patient with a retinal AVM suggestive of Wyburn–Mason syndrome should undergo evaluation for:

Intracranial and orbital AVMs.

Initial imaging usually includes:

• MRI of the brain and orbits
• MRA

CTA may be used in selected circumstances.

Role of Catheter Cerebral Angiography

Digital subtraction angiography provides the most detailed assessment of:

• Feeding arteries
• Nidus architecture
• Venous drainage
• High-risk aneurysms

It is not required for every incidental retinal AVM.

It is generally reserved when:

• MRI/MRA identifies an intracranial AVM
• Treatment is being considered
• Detailed neurovascular anatomy is required

Why Neurology or Neurosurgery Referral Matters

Retinal AVMs can be the first visible sign of a clinically silent:

Cerebral AVM.

Identification of a retinal racemose malformation therefore warrants neurovascular evaluation even when the patient has:

No neurologic symptoms.

Important Ocular Complications

Although many retinal AVMs remain stable, complications can include:

• Retinal vein occlusion
• Retinal ischemia
• Macular edema
• Retinal hemorrhage
• Vitreous hemorrhage
• Secondary neovascularization
• Secondary glaucoma
• Optic neuropathy

Retinal Vascular Occlusion

Abnormal hemodynamics may predispose to:

• Branch retinal vein occlusion
• Central retinal vein occlusion
• Less commonly arterial compromise

Occlusion may produce:

• Retinal hemorrhage
• Macular edema
• Ischemia
• Neovascularization

Neovascular Glaucoma

Extensive retinal ischemia after vascular occlusion may produce:

VEGF-driven iris and angle neovascularization.

This may lead to:

Neovascular glaucoma.

Treatment requires management of both:

• Retinal ischemia
• Elevated IOP

Glaucoma From Elevated Episcleral Venous Pressure

A second glaucoma mechanism can occur when orbital or episcleral AV communications raise:

Episcleral venous pressure.

Clinical clues include:

• Dilated episcleral vessels
• Elevated IOP
• Open angle
• Blood in Schlemm canal on gonioscopy in some cases

This mechanism differs from neovascular glaucoma.

Why the Glaucoma Mechanism Must Be Identified

Management differs substantially between:

Ischemic neovascular glaucoma

Requires suppression of retinal VEGF drive.

Elevated episcleral venous pressure

Results from impaired aqueous drainage against an abnormally high venous pressure.

Gonioscopy and retinal examination are therefore essential.

Treating Elevated IOP

Medical treatment may include:

• Topical beta-blocker
• Carbonic anhydrase inhibitor
• Alpha-2 agonist
• Prostaglandin analogue

Systemic acetazolamide may be used when stronger short-term IOP lowering is needed.

Role of Miotics

Older references listed miotics among routine glaucoma therapies.

They are not particularly useful for the typical mechanisms of glaucoma in Wyburn–Mason syndrome and are:

Not a preferred modern first-line strategy.

Treatment should be based on the actual glaucoma mechanism.

Treating Neovascular Complications

When retinal ischemia produces neovascularization:

• Panretinal photocoagulation (PRP) may be indicated
• Intravitreal anti-VEGF can provide rapid temporary regression of neovascularization

Anti-VEGF is an adjunct because:

The underlying ischemic retina remains the definitive treatment target.

Important Correction About Laser Treatment

The congenital retinal AVM itself is generally:

Not treated with destructive laser simply because it is present.

Direct photocoagulation of a high-flow retinal AVM can be hazardous and is rarely appropriate.

Laser is primarily directed at:

Secondary ischemic or neovascular complications.

Vitreous Hemorrhage

Nonclearing vitreous hemorrhage may require:

Pars plana vitrectomy

especially if:

• Vision remains substantially reduced
• Retinal traction is present
• Retinal pathology cannot otherwise be monitored

Amblyopia

Children with unilateral visual impairment may develop:

Amblyopia.

When appropriate, management may include:

• Optical correction
• Patching
• Atropine penalization in selected cases

However, amblyopia treatment can only improve the portion of vision loss attributable to abnormal visual development, not structural retinal damage.

Strabismus

Strabismus may occur from:

• Poor unilateral vision
• Cranial nerve dysfunction
• Orbital involvement

Management depends on:

• Visual potential
• Stability
• Neurologic status

Surgery can be considered when appropriate.

Management of the Retinal AVM Itself

For an uncomplicated retinal AVM:

Observation is usually the preferred strategy.

Follow with:

• Visual acuity
• IOP
• Dilated fundus examination
• Photography
• OCT when useful

Treatment is reserved for:

Complications rather than the vascular anomaly itself.

Does the AVM Spontaneously Disappear?

True spontaneous involution is:

Uncommon and should not be expected.

Most congenital retinal AVMs are structurally persistent, although their appearance and complications may remain stable for long periods.

Treatment of Intracranial AVMs

Management of a cerebral AVM is highly individualized.

Options can include:

• Observation
• Endovascular embolization
• Microsurgical resection
• Stereotactic radiosurgery
• Multimodal treatment

The decision depends on:

• AVM size
• Location
• Venous drainage
• Previous hemorrhage
• Neurologic symptoms
• Treatment risk

Why Not Every Brain AVM Is Treated

Intervention itself can cause:

• Stroke
• Hemorrhage
• Neurologic deficit
• Death

Therefore neurosurgical management requires careful comparison of:

Natural-history risk vs treatment risk.

Retinal AVM presence alone is not an automatic indication for brain AVM intervention.

Oral and Maxillofacial Precautions

If facial, mandibular, or oral AVMs are present, apparently routine procedures such as:

• Dental extraction
• Biopsy
• Oral surgery

can provoke:

Severe hemorrhage.

Relevant vascular imaging should precede invasive procedures when a significant maxillofacial AVM is suspected.

Key Diagnostic Alternatives

Important differentials include:

• Congenital retinal macrovessel
• Retinal cavernous hemangioma
• Retinal capillary hemangioblastoma
• Vasoproliferative retinal tumor
• Retinal telangiectasia
• Retinal collaterals
• Intraretinal microvascular abnormalities
• Sturge-Weber syndrome

Wyburn–Mason vs Von Hippel-Lindau Disease

Wyburn–Mason

• Direct retinal artery-vein communications
• Markedly dilated racemose vessels
• Usually unilateral
• Associated with CNS AVMs
• No discrete vascular tumor required

VHL

• Retinal capillary hemangioblastoma
• Orange-red tumor mass
• Prominent feeding arteriole and draining venule
• Often multiple/bilateral
• Associated with RCC, CNS hemangioblastoma, pheochromocytoma, etc.

Wyburn–Mason vs Retinal Cavernous Hemangioma

Retinal cavernous hemangioma consists of:

• Clusters of thin-walled venous aneurysms
• “Bunch of grapes” appearance
• Slow blood flow
• Plasma-erythrocyte layering

This is very different from the:

High-flow artery-to-vein shunting of Wyburn–Mason syndrome.

Wyburn–Mason vs Sturge-Weber Syndrome

Sturge-Weber syndrome classically involves:

• Port-wine birthmark
• Leptomeningeal capillary-venous malformation
• Diffuse choroidal hemangioma
• Glaucoma

Wyburn–Mason instead features:

True high-flow arteriovenous malformations of the retina and CNS.

Wyburn–Mason vs Congenital Retinal Macrovessel

A congenital retinal macrovessel is usually:

• A single anomalous large retinal vessel
• Often crossing the horizontal raphe
• Frequently incidental

It does not usually produce the extensive direct arteriovenous shunting seen in:

Racemose retinal AVMs.

Long-Term Monitoring

Patients should receive periodic:

Ophthalmic surveillance

for:

• Vision
• IOP
• Retinal vascular complications
• New hemorrhage
• Neovascularization

Neurologic follow-up depends on the presence and anatomy of associated CNS disease.

When Urgent Assessment Is Needed

Patients require urgent evaluation for:

• Sudden severe headache
• New neurologic deficit
• Seizure
• Altered consciousness
• Sudden visual loss
• Painful red eye with elevated IOP
• Vitreous hemorrhage

These may represent:

• Intracranial hemorrhage
• Retinal vascular occlusion
• Neovascular glaucoma
• Other acute complications

Expected Ocular Course

Prognosis varies greatly.

A limited peripheral retinal AVM may remain stable with excellent vision.

More extensive lesions involving:

• Macula
• Optic nerve
• Major retinal circulation

can cause significant permanent visual impairment.

What Determines Neurologic Prognosis

Systemic prognosis depends principally on:

• Location and size of cerebral AVMs
• Previous intracranial hemorrhage
• Associated aneurysms
• Neurologic deficits
• Feasibility and risk of treatment

Some patients remain neurologically asymptomatic throughout life.

High-Yield Takeaways

• Wyburn–Mason syndrome is a rare, usually sporadic congenital disorder characterized by retinal AVMs associated with ipsilateral cerebral, orbital, or craniofacial AVMs.
• It is also called Bonnet–Dechaume–Blanc syndrome or retinocephalic vascular malformation syndrome.
• An isolated retinal AVM does not automatically establish Wyburn–Mason syndrome; associated CNS disease should be sought.
• Retinal AVMs consist of direct artery-to-vein communications with absent or reduced intervening capillary beds.
• The classic fundus appearance is massively dilated, tortuous arteries and veins with direct arteriovenous shunting.
• The traditional Archer classification includes Group 1 mild AV communication, Group 2 direct AV communication, and Group 3 extensive racemose malformation.
• More extensive Group 2 and 3 lesions have a stronger association with intracranial AVMs.
• FA classically shows rapid arteriovenous transit with little leakage in uncomplicated lesions.
• OCT and OCTA can document retinal structural distortion and abnormal vascular channels.
• Discovery of a significant retinal AVM should prompt brain/orbital MRI and vascular imaging, usually MRI/MRA initially.
• Catheter cerebral angiography is reserved for selected patients when an intracranial AVM requires detailed characterization or treatment planning.
• The retinal AVM itself is usually observed rather than directly treated.
• Important ocular complications include retinal vein occlusion, retinal ischemia, vitreous hemorrhage, macular edema, neovascularization, and glaucoma.
• Glaucoma may arise from either retinal ischemia causing neovascular glaucoma or elevated episcleral venous pressure from orbital AV shunting.
• PRP and anti-VEGF are used for secondary ischemic neovascular complications, not routinely to eradicate the congenital AVM.
• Vitrectomy may be required for nonclearing vitreous hemorrhage or tractional complications.
• Severe oral or maxillofacial AVMs may produce dangerous hemorrhage during dental or surgical procedures.
• Cerebral AVM management may involve observation, embolization, microsurgery, stereotactic radiosurgery, or combinations, depending on individualized hemorrhage and treatment risk.
• Wyburn–Mason is distinct from VHL, which produces retinal capillary hemangioblastomas, and from Sturge-Weber, which produces capillary-venous malformations and diffuse choroidal hemangioma.
• Patients require long-term ophthalmic and neurologic surveillance because complications can develop despite years of stability.

High-Yield Takeaways

Ophthalmology – Wilson’s Disease

What the Disorder Represents

Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by pathogenic variants in ATP7B.

Defective hepatic copper handling causes:

• Impaired biliary copper excretion
• Progressive hepatic copper accumulation
• Release of excess copper into the circulation
• Deposition in the brain, cornea, kidneys, and other tissues

The classic ophthalmic sign is:

Kayser-Fleischer (KF) ring — copper deposition in Descemet membrane at the peripheral cornea.

Another characteristic ocular manifestation is:

Sunflower cataract.

The Genetic Defect

Wilson disease is caused by pathogenic variants in:

ATP7B on chromosome 13q14.3.

ATP7B normally participates in:

• Transport of excess copper into bile
• Incorporation of copper into apoceruloplasmin

Loss of ATP7B function therefore leads to:

Hepatic copper retention and reduced circulating ceruloplasmin.

How the Disorder Is Inherited

Inheritance is:

Autosomal recessive.

For two carrier parents, each pregnancy carries approximately:

• 25% chance of an affected child
• 50% chance of a carrier
• 25% chance of an unaffected noncarrier

Siblings of an affected patient should generally undergo:

Targeted screening.

Important Modern Correction About Genetic Testing

Older references described molecular testing as useful mainly after identifying a familial mutation.

This is outdated.

ATP7B sequencing and deletion/duplication analysis are now routinely available and can:

• Confirm the diagnosis
• Clarify equivocal biochemical testing
• Screen relatives
• Support reproductive counseling

A negative molecular test does not completely exclude WD when clinical suspicion remains high.

Why Copper Accumulates

Dietary copper is absorbed from the gastrointestinal tract and delivered to the liver.

Normally, the liver:

• Incorporates copper into ceruloplasmin
• Excretes excess copper into bile

In WD:

Biliary copper excretion fails.

Copper therefore accumulates within hepatocytes and eventually causes:

• Oxidative injury
• Mitochondrial dysfunction
• Hepatitis
• Fibrosis
• Cirrhosis

How Extrahepatic Disease Develops

As hepatocyte storage capacity is exceeded, toxic copper enters the circulation and deposits in:

• Basal ganglia
• Cornea
• Kidneys
• Other tissues

This produces the neurologic, psychiatric, ocular, and renal manifestations of WD.

Who Typically Presents With Wilson Disease

Presentation varies by age.

Children and Adolescents

More commonly present with:

Hepatic disease

such as:

• Asymptomatic transaminase elevation
• Chronic hepatitis
• Cirrhosis
• Acute liver failure

Adolescents and Young Adults

More commonly develop:

• Neurologic symptoms
• Psychiatric symptoms
• Mixed hepatic-neurologic disease

However, presentation can occur over a much wider age range.

Hepatic Manifestations

Liver disease may include:

• Elevated aminotransferases
• Fatty liver
• Chronic hepatitis
• Cirrhosis
• Portal hypertension
• Jaundice
• Ascites
• Acute liver failure

WD should be considered in:

Unexplained liver disease in a child, adolescent, or young adult.

A Particularly Important Hepatic Presentation

Wilson-related acute liver failure may be accompanied by:

• Coombs-negative hemolytic anemia
• Jaundice
• Coagulopathy
• Renal dysfunction

This is a medical emergency and may require:

Urgent liver transplantation.

Neurologic Manifestations

Neurologic disease commonly includes:

• Tremor
• Dysarthria
• Dystonia
• Parkinsonism
• Ataxia
• Chorea
• Drooling
• Gait disturbance

A characteristic proximal upper-extremity tremor may produce a:

“Wing-beating” appearance.

Psychiatric Manifestations

Psychiatric or behavioral symptoms may precede obvious neurologic disease.

These include:

• Personality change
• Depression
• Irritability
• Anxiety
• Reduced school or work performance
• Psychosis in selected patients

A young patient with unexplained psychiatric symptoms plus:

• Liver abnormalities
• Movement disorder
• KF rings

should prompt evaluation for WD.

Ocular Motor Abnormalities

Neurologic WD may affect eye movements.

Reported abnormalities include:

• Impaired smooth pursuit
• Saccadic abnormalities
• Vertical gaze abnormalities in some patients

These are secondary to CNS involvement rather than primary ocular disease.

Kayser-Fleischer Rings

The hallmark ocular sign is:

Copper deposition within Descemet membrane of the peripheral cornea.

The ring may appear:

• Golden-brown
• Green-brown
• Gray-brown

It is most easily detected by:

Slit-lamp examination.

How Kayser-Fleischer Rings Develop

Copper deposition often begins at:

• Superior cornea
• Inferior cornea

and subsequently progresses circumferentially.

Early incomplete arcs can therefore be missed without careful slit-lamp examination.

Where the Copper Is Located

KF rings occur primarily in:

Descemet membrane near the limbus.

They should not be confused with:

• Arcus
• Pigment on the anterior corneal surface
• Fleischer ring of keratoconus

How Common Are KF Rings?

They are present in:

Most patients with neurologic Wilson disease

but are less frequent in patients presenting only with hepatic disease.

Therefore:

Absence of a KF ring does not exclude Wilson disease.

Are KF Rings Specific?

They are highly characteristic in the appropriate clinical setting but are not completely specific.

Similar peripheral corneal copper deposition can occasionally occur with:

Chronic cholestatic liver disease.

Clinical and biochemical context therefore matters.

Effect of Treatment on KF Rings

With effective copper-lowering therapy:

• KF rings may fade
• Their density may decrease
• They can disappear over time

Persistence does not necessarily indicate treatment failure if systemic copper control is otherwise satisfactory.

Sunflower Cataract

Another classic ocular finding is the:

Sunflower cataract.

It results from copper deposition in the:

• Anterior lens capsule
• Sometimes posterior capsule

The appearance consists of:

• Central disc-like opacity
• Radiating petal-like spokes

Visual Effect of Sunflower Cataract

Despite its dramatic appearance, a sunflower cataract often causes:

Relatively little visual impairment.

It may partially or completely regress with successful copper chelation.

Other Ophthalmic Findings

Less common or nonspecific findings include:

• Reduced vision secondary to neurologic disease
• Ocular motility abnormalities
• Rare optic nerve abnormalities

The major ophthalmic diagnostic findings remain:

KF rings and sunflower cataract.

How the Diagnosis Is Established

No single laboratory test establishes WD in every patient.

Diagnosis relies on a combination of:

• Clinical findings
• Serum ceruloplasmin
• 24-hour urinary copper
• Slit-lamp examination for KF rings
• Hepatic copper measurement when necessary
• ATP7B genetic testing

A structured approach such as the:

Leipzig scoring system

is commonly used when the diagnosis is uncertain.

The Leipzig Diagnostic Approach

The Leipzig score assigns weight to findings such as:

• KF rings
• Neurologic manifestations
• Serum ceruloplasmin
• Coombs-negative hemolysis
• Hepatic copper
• Urinary copper
• ATP7B pathogenic variants

A sufficiently high score strongly supports:

Wilson disease.

Serum Ceruloplasmin

Serum ceruloplasmin is often:

Low

in WD.

A markedly reduced value strongly supports the diagnosis, but:

Ceruloplasmin alone is neither sensitive nor specific enough to diagnose WD.

Why Ceruloplasmin Can Mislead

Low ceruloplasmin can also occur with:

• Severe liver failure
• Protein-losing enteropathy
• Nephrotic syndrome
• Malnutrition
• Heterozygous ATP7B carrier state

Conversely, ceruloplasmin may be normal or elevated because it is an:

Acute-phase reactant.

Levels may increase with:

• Inflammation
• Pregnancy
• Estrogen exposure

Thus normal ceruloplasmin does not exclude WD.

Serum Copper

Total serum copper may paradoxically be:

Low

because much circulating copper is normally carried by ceruloplasmin.

However, the biologically toxic:

Non-ceruloplasmin-bound copper

is increased in untreated WD.

Limitation of Calculated “Free Copper”

Traditional calculated non-ceruloplasmin copper can be inaccurate because:

• Ceruloplasmin assays vary
• Total serum copper assays vary
• The calculation compounds assay error

It should not be interpreted in isolation.

More direct assays of exchangeable copper are emerging in specialist centers.

24-Hour Urinary Copper

Untreated symptomatic patients usually have increased urinary copper excretion.

A level of approximately:

>100 µg/24 hours in symptomatic adults

strongly supports WD, although thresholds differ by age and clinical setting.

Moderately elevated values may occur in other liver diseases.

Penicillamine Challenge Testing

Older protocols used a:

D-penicillamine challenge test

particularly in children.

This approach now has a much more limited role because of:

• Variable diagnostic performance
• Better genetic testing
• Improved biochemical assessment

It should not be considered a routine modern diagnostic requirement.

Hepatic Copper Quantification

When diagnosis remains uncertain, liver biopsy may be used to measure:

Hepatic copper concentration.

A concentration:

>250 µg/g dry weight

strongly supports Wilson disease.

However, sampling variability can occur, particularly in:

• Advanced cirrhosis

and elevated hepatic copper can also occur in:

• Severe cholestatic disorders

So results require clinical interpretation.

Liver Biopsy Is Not Always Required

Modern diagnosis often can be established without biopsy when there is a convincing combination of:

• KF rings
• Neurologic disease
• Low ceruloplasmin
• Elevated urinary copper
• ATP7B pathogenic variants

Biopsy is most useful when:

The diagnosis remains ambiguous.

Histopathologic Liver Findings

Liver histology may show:

• Steatosis
• Chronic hepatitis
• Fibrosis
• Cirrhosis

These are not specific.

Routine histochemical copper staining has limited sensitivity because copper distribution can be:

Patchy.

Quantitative hepatic copper is more useful.

Brain MRI

MRI is preferred over CT for neurologic WD.

Commonly affected structures include:

• Putamen
• Caudate
• Globus pallidus
• Thalamus
• Brainstem

MRI may show:

• T2/FLAIR signal abnormalities
• Atrophy in advanced disease
• Other basal ganglia changes

The “Face of the Giant Panda” Sign

A classic but uncommon MRI sign is the:

“Face of the giant panda”

appearance in the midbrain.

It is associated with Wilson disease but is:

Not required and not sufficiently sensitive to use as a diagnostic test.

Renal Manifestations

Copper toxicity can produce proximal tubular dysfunction leading to:

• Fanconi syndrome
• Aminoaciduria
• Phosphaturia
• Glycosuria despite normal serum glucose
• Nephrolithiasis

Renal disease is less prominent than hepatic or neurologic involvement.

Hematologic Manifestations

WD can cause:

Coombs-negative intravascular hemolysis

especially during acute liver failure.

Sudden release of hepatic copper damages erythrocytes.

Skeletal and Other Manifestations

Patients may develop:

• Arthralgia
• Osteopenia
• Premature osteoarthritis
• Rare cardiac abnormalities

These manifestations are less diagnostically prominent.

Important Diagnostic Alternatives

Depending on presentation, consider:

Hepatic Disease

• Viral hepatitis
• Autoimmune hepatitis
• Drug-induced liver injury
• Metabolic liver disease
• Alpha-1 antitrypsin deficiency

Neurologic Disease

• Young-onset Parkinsonism
• Huntington disease
• Dystonia syndromes
• Mitochondrial disease

Corneal Ring

• Chronic cholestatic copper deposition
• Other peripheral corneal pigmentation disorders

Screening Family Members

First-degree relatives, especially siblings, should be assessed because early WD may be:

Completely asymptomatic.

Evaluation may include:

• ATP7B genetic testing
• Ceruloplasmin
• Liver tests
• Urinary copper
• Ophthalmic examination

when appropriate.

Early diagnosis can prevent irreversible organ damage.

The Core Treatment Principle

Treatment must:

Reduce toxic copper and prevent its reaccumulation for life.

Therapy is lifelong, including in asymptomatic patients once the diagnosis is established.

Stopping therapy can cause:

• Hepatic decompensation
• Neurologic deterioration
• Acute liver failure

Copper Chelation

Chelators bind copper and increase urinary excretion.

The major agents are:

• D-penicillamine
• Trientine

Both can effectively reduce body copper stores.

D-Penicillamine

D-penicillamine was historically the standard first-line chelator.

Potential adverse effects include:

• Neurologic worsening after initiation
• Bone marrow suppression
• Proteinuria
• Nephrotoxicity
• Autoimmune reactions
• Skin abnormalities

Pyridoxine supplementation is generally given because penicillamine interferes with vitamin B6 metabolism.

Trientine

Trientine is now widely used as an alternative and in many settings is favored because of a more favorable adverse-effect profile than penicillamine.

It can also occasionally cause:

• Iron deficiency
• Cytopenia
• Neurologic worsening

Treatment selection is individualized with hepatology or a Wilson disease specialist.

Important Modern Correction About Zinc

Older sources sometimes recommended administering zinc together with trientine.

In practice:

Chelators and zinc should generally be separated in time

because they can interfere with one another’s absorption and action.

They are not simply taken simultaneously as a routine combination.

Zinc Therapy

Zinc induces intestinal:

Metallothionein

which binds dietary copper within enterocytes and reduces systemic absorption.

Zinc is particularly useful for:

• Presymptomatic disease
• Maintenance therapy
• Selected patients who cannot tolerate chelators

Its role in symptomatic disease depends on severity and specialist strategy.

Zinc Is Slower Than Chelation

Because zinc primarily blocks new copper absorption rather than rapidly removing stored copper, it acts more slowly.

Therefore severe:

• Hepatic disease
• Neurologic disease

often requires more active decoppering therapy.

Risk of Neurologic Worsening

A clinically important complication of chelation is:

Initial worsening of neurologic symptoms.

This is thought to result from mobilization of tissue copper and redistribution.

It can occur with:

• Penicillamine
• Trientine

though historically it has been particularly associated with penicillamine.

Slow dose escalation may be used in neurologic presentations.

Liver Transplantation

Liver transplantation is potentially curative for the hepatic metabolic defect.

It is indicated particularly for:

• Acute liver failure from Wilson disease
• Decompensated cirrhosis refractory to medical therapy

Transplantation restores normal hepatic ATP7B function and copper handling.

Treatment During Pregnancy

Women with WD should generally:

Continue anti-copper therapy during pregnancy

because stopping treatment can cause severe maternal deterioration.

Drug choice and dose require:

• Hepatology
• Obstetric
• Genetic counseling input

Doses may be adjusted during pregnancy and around delivery.

Dietary Copper Restriction

Dietary restriction is most important during the early treatment phase.

Foods particularly high in copper include:

• Liver
• Shellfish
• Nuts
• Chocolate
• Mushrooms

Diet alone is:

Not sufficient treatment.

Drinking Water and Copper Exposure

Patients should consider the copper content of:

• Well water
• Old copper plumbing
• Copper cookware

when environmental exposure may be substantial.

Routine extreme dietary restriction is not necessary once effective medical therapy is established.

Monitoring Treatment

Long-term monitoring may include:

• Liver enzymes
• INR
• CBC
• Creatinine
• Urinalysis
• 24-hour urinary copper
• Clinical neurologic assessment
• Treatment adherence

Monitoring strategy differs according to whether the patient receives:

• Chelator therapy
• Zinc

Why Monitoring Urinary Copper Matters

During chelation, urinary copper helps assess:

• Treatment effect
• Adherence
• Possible overtreatment

Inappropriately low values may indicate:

• Nonadherence
• Excessive depletion

depending on treatment context.

Watching for Copper Deficiency

Excessive treatment can cause:

Iatrogenic copper deficiency.

Possible manifestations include:

• Anemia
• Neutropenia
• Myelopathy
• Peripheral neuropathy

Copper-lowering therapy therefore requires careful monitoring rather than simply maximizing drug dose.

Ophthalmic Follow-Up

Slit-lamp examination can document:

• KF ring density
• Regression with treatment
• Sunflower cataract

However, systemic copper control should be assessed primarily through:

Clinical and biochemical monitoring, not by the corneal ring alone.

Do Kayser-Fleischer Rings Require Ocular Treatment?

No.

KF rings are:

A diagnostic marker, not an ocular lesion requiring laser or surgery.

They fade as systemic copper burden decreases.

Does Sunflower Cataract Require Surgery?

Usually not.

Because sunflower cataracts may:

• Cause little visual impairment
• Regress with copper-lowering treatment

cataract surgery is rarely required solely for this finding.

Genetic Counseling

Because WD is autosomal recessive, counseling should address:

• Sibling testing
• Carrier status
• Reproductive implications
• Partner testing in selected circumstances

Identifying presymptomatic affected relatives is especially valuable because:

Early treatment can prevent disease manifestations.

Expected Long-Term Course

Without treatment, Wilson disease can cause:

• Progressive cirrhosis
• Severe neurologic disability
• Acute liver failure
• Death

With early diagnosis and lifelong effective treatment:

Life expectancy can approach normal.

Neurologic Prognosis

Neurologic recovery may take:

• Months
• Years

and may be incomplete.

Persistent problems can include:

• Dysarthria
• Dystonia
• Tremor

Early treatment before extensive CNS injury offers the best prognosis.

Ocular Prognosis

Ocular findings usually improve with systemic treatment.

• KF rings often fade
• Sunflower cataract may regress
• Neither usually causes major permanent visual loss

Thus the eye is particularly valuable as a:

Diagnostic window into systemic copper toxicity.

High-Yield Takeaways

• Wilson disease is an autosomal recessive copper-transport disorder caused by ATP7B pathogenic variants on chromosome 13q14.3.
• ATP7B normally facilitates biliary copper excretion and incorporation of copper into ceruloplasmin.
• Copper first accumulates in the liver, then damages the brain, cornea, kidneys, and other tissues.
• Children more commonly present with hepatic disease, whereas adolescents and young adults may develop neurologic or psychiatric disease.
• The classic ophthalmic sign is the Kayser-Fleischer ring, representing copper deposition in peripheral Descemet membrane.
• KF deposition usually begins superiorly and inferiorly before becoming circumferential.
• Most neurologic WD patients have KF rings, but their absence does not exclude hepatic Wilson disease.
• KF rings are highly characteristic but can rarely occur with other severe cholestatic disorders.
• Sunflower cataract is another characteristic copper-deposition sign and often causes little visual disability.
• Diagnosis uses a combination of ceruloplasmin, 24-hour urinary copper, KF rings, hepatic copper, and ATP7B genetic testing rather than any single test.
• The Leipzig score is useful when the diagnosis is uncertain.
• Low ceruloplasmin supports WD but is neither fully sensitive nor specific; normal levels do not exclude disease.
• Symptomatic untreated patients commonly have 24-hour urinary copper >100 µg/day.
• Hepatic copper >250 µg/g dry weight strongly supports WD, although biopsy is no longer required in every patient.
• Modern ATP7B genetic testing is widely available and is not restricted to family screening.
• Neurologic MRI commonly involves the basal ganglia; the “giant panda” sign is classic but uncommon.
• Treatment is lifelong and includes copper chelation with trientine or D-penicillamine and/or zinc according to disease stage.
• Chelation can initially worsen neurologic symptoms, particularly in patients with neurologic presentation.
• Zinc reduces intestinal copper absorption and is especially useful in presymptomatic and maintenance therapy.
• Chelators and zinc should generally be separated in time, rather than routinely taken together.
• Wilson-related acute liver failure or refractory decompensated cirrhosis requires urgent consideration of liver transplantation.
• Anti-copper treatment generally needs to continue during pregnancy under specialist supervision.
• Excessive therapy can produce copper deficiency with cytopenias or neurologic injury, so biochemical monitoring is essential.
• KF rings and sunflower cataracts themselves usually require no direct ophthalmic treatment.
• With early recognition and sustained therapy, systemic and ocular prognosis can be excellent; untreated Wilson disease can be fatal.

High-Yield Takeaways

Ophthalmology – Weill-Marchesani Syndrome

What the Disorder Represents

Weill-Marchesani syndrome (WMS) is a rare inherited connective-tissue disorder characterized by the combination of:

• Microspherophakia
• Ectopia lentis
• High lenticular myopia
• Secondary glaucoma
• Short stature
• Brachydactyly
• Joint stiffness

The most vision-threatening ophthalmic complication is:

Pupillary-block angle-closure glaucoma caused by the small, spherical, anteriorly displaced lens.

The Characteristic Body Habitus

The systemic phenotype contrasts strongly with Marfan syndrome.

Typical findings include:

• Short stature
• Broad, short fingers and toes
• Brachydactyly
• Reduced joint mobility
• Muscular or stocky body habitus

Not every patient demonstrates every systemic feature to the same degree.

The Genetic Basis

Both:

• Autosomal recessive
• Autosomal dominant

forms occur.

Important genes include:

• ADAMTS10 – classically autosomal recessive WMS
• FBN1 – autosomal dominant WMS
• LTBP2 – associated with recessive WMS phenotypes in some families

Related disorders involving genes such as ADAMTS17 may produce a Weill-Marchesani-like phenotype.

Why FBN1 Can Cause Both Marfan and Weill-Marchesani Phenotypes

Fibrillin-1, encoded by FBN1, is a major extracellular matrix component.

Different pathogenic variants can produce very different phenotypes.

Thus:

• Some FBN1 variants cause Marfan syndrome
• Other variants can produce autosomal dominant Weill-Marchesani syndrome

despite their almost opposite skeletal appearances.

How the Lens Becomes Abnormal

The zonular apparatus and extracellular matrix develop abnormally.

The crystalline lens becomes:

• Smaller in equatorial diameter
• Thicker anteroposteriorly
• More spherical

This is termed:

Microspherophakia.

The abnormal zonules also predispose to:

• Lens subluxation
• Lens dislocation

Why Microspherophakia Causes Myopia

A spherical lens has:

Greater refractive power

than a normal flatter crystalline lens.

Patients therefore frequently develop substantial:

Lenticular myopia.

The refractive error may change as the lens becomes more mobile or shifts position.

Why the Anterior Chamber Becomes Shallow

The thick spherical lens can sit relatively far forward.

This produces:

• Shallow anterior chamber
• Increased iris-lens contact
• Narrow iridocorneal angle

The result is a strong predisposition to:

Pupillary block.

Mechanism of Angle-Closure Glaucoma

Aqueous cannot move normally from the posterior to anterior chamber because of excessive iris-lens contact.

Pressure builds behind the iris, producing:

Iris bombé → peripheral angle closure → elevated IOP.

Repeated episodes may eventually create:

Peripheral anterior synechiae and chronic angle closure.

Lens Subluxation

Abnormal zonular support permits the microspherophakic lens to move.

It may become:

• Mildly decentered
• Markedly subluxated
• Completely dislocated

Unlike the classic superotemporal displacement in Marfan syndrome, WMS lens displacement can be:

Variable in direction.

Anterior Lens Dislocation

The lens can rarely dislocate into the anterior chamber.

This may cause:

• Acute pupillary block
• Severe angle closure
• Corneal endothelial damage
• Markedly elevated IOP

This is an:

Urgent surgical problem.

When the Syndrome Becomes Apparent

Systemic characteristics may be recognized during childhood.

Ocular complications may appear later and include:

• Progressive myopia
• Lens subluxation
• Angle narrowing
• Glaucoma

Therefore lifelong ophthalmic surveillance is important.

Typical Ocular Findings

Important examination findings include:

• Microspherophakia
• High lenticular myopia
• Shallow anterior chamber
• Iridodonesis
• Phacodonesis
• Ectopia lentis
• Narrow angles
• Secondary glaucoma

The lens equator may become visible after dilation if zonular loss is substantial.

Recognizing Microspherophakia at the Slit Lamp

Features include:

• Small lens diameter
• Increased lens thickness
• More spherical contour
• Abnormally deep curvature

With zonular weakness, the lens may also show:

Phacodonesis.

Gonioscopy

Gonioscopy is important for assessing:

• Angle width
• Peripheral anterior synechiae
• Chronic angle closure

It should be performed carefully because the lens position can change with:

• Accommodation
• Medications
• Body position

Anterior Segment Imaging

Useful modalities include:

• Anterior segment OCT
• Ultrasound biomicroscopy

These can document:

• Lens position
• Anterior chamber depth
• Iris configuration
• Angle closure
• Zonular abnormalities

UBM is particularly useful when the lens-iris relationship is difficult to visualize.

Refractive Assessment

Refraction may reveal:

High myopia caused predominantly by the lens rather than axial elongation.

This distinction matters because lens extraction can produce a major refractive change.

Glaucoma Evaluation

Patients should undergo:

• IOP measurement
• Gonioscopy
• Optic nerve examination
• RNFL OCT
• Visual field testing when age and cooperation permit

Glaucoma may develop gradually even without dramatic acute attacks.

Important Differential Diagnoses

The major differential for ectopia lentis includes:

• Marfan syndrome
• Homocystinuria
• Familial isolated ectopia lentis
• Ectopia lentis et pupillae
• Sulfite oxidase deficiency
• Molybdenum cofactor deficiency
• Trauma
• Aniridia
• Congenital glaucoma

Microspherophakia narrows the differential considerably.

Weill-Marchesani vs Marfan Syndrome

Weill-Marchesani Syndrome

• Short stature
• Brachydactyly
• Joint stiffness
• Microspherophakia
• High lenticular myopia
• Pupillary-block glaucoma

Marfan Syndrome

• Tall stature
• Arachnodactyly
• Joint laxity
• Ectopia lentis without typical microspherophakia
• Aortic root disease

The body habitus is almost the mirror image.

Weill-Marchesani vs Homocystinuria

Homocystinuria may cause:

• Ectopia lentis
• Developmental delay
• Thromboembolic disease
• Marfanoid habitus

Lens dislocation is often classically inferonasal, although direction is not absolute.

Microspherophakia and the typical short, brachydactylic phenotype favor:

Weill-Marchesani syndrome.

Molecular Diagnosis

Modern genetic testing can identify pathogenic variants in genes associated with WMS.

Testing is useful for:

• Confirming the diagnosis
• Determining inheritance pattern
• Testing relatives
• Reproductive counseling

A negative test does not completely exclude the diagnosis because not every causative variant is necessarily detected.

Systemic Evaluation

Evaluation should include attention to:

• Height
• Hands and feet
• Joint mobility
• Cardiovascular system

Possible cardiovascular abnormalities have been reported, including:

• Valvular abnormalities
• Patent ductus arteriosus
• Aortic abnormalities in selected genotypes

Cardiology evaluation is reasonable when clinically indicated.

Genetic Counseling

Inheritance risk depends on the molecular subtype.

Autosomal Dominant WMS

An affected individual typically has approximately a:

50% chance of transmitting the pathogenic variant to each child.

Autosomal Recessive WMS

Parents are typically carriers, with each pregnancy having:

• 25% affected
• 50% carrier
• 25% unaffected/noncarrier

when both parents carry the same pathogenic variant.

Managing the Refractive Error

Early disease may be managed with:

• Spectacles
• Contact lenses

particularly when myopia is the main visual problem.

Children require assessment for:

• Amblyopia
• Strabismus

because uncorrected lenticular myopia can interfere with visual development.

Treating Elevated IOP

Medical therapy generally begins with:

Aqueous suppressants, such as:

• Beta-blocker
• Topical carbonic anhydrase inhibitor
• Alpha-2 agonist when age appropriate

Prostaglandin analogues may also be used for chronic pressure control.

Pediatric Medication Caution

Brimonidine should be avoided in infants and very young children, particularly under approximately 2 years, because it can cause:

• CNS depression
• Somnolence
• Apnea
• Hypotension

Medication choice must therefore be age appropriate.

Why Miotics Are Usually Avoided

Miotics such as pilocarpine can worsen the lens-iris relationship by:

• Relaxing zonular tension
• Allowing the lens to move anteriorly
• Increasing pupillary block

Therefore they are generally:

Avoided in microspherophakia-associated angle closure.

Why Mydriasis Can Also Be Risky

Mydriatic agents may precipitate angle closure in an already crowded anterior segment.

However, dilation is sometimes necessary for diagnosis.

Therefore pharmacologic dilation should be undertaken:

With awareness of the angle anatomy and IOP risk.

Acute Angle Closure

Acute attacks may present with:

• Severe ocular pain
• Headache
• Blurred vision
• Halos
• Red eye
• Nausea or vomiting
• Markedly elevated IOP

This requires urgent pressure lowering and correction of the underlying pupillary block.

Initial Management of Acute Angle Closure

Treatment may include:

• Topical aqueous suppressants
• Systemic acetazolamide when appropriate
• Hyperosmotic therapy in severe cases

Miotics are generally avoided because of the abnormal zonular-lenticular anatomy.

Definitive management often requires:

Laser iridotomy and/or lens extraction.

Laser Peripheral Iridotomy

LPI can bypass pupillary block by allowing aqueous to move directly from the posterior to anterior chamber.

It can be useful when:

Pupillary block is the dominant mechanism.

Important Modern Correction About Prophylactic Iridotomy

Older sources sometimes recommended routine prophylactic peripheral iridotomy for virtually all patients.

A more individualized approach is appropriate.

LPI is particularly considered when there is:

• Narrow/occludable angle
• Previous pupillary-block episode
• Progressive anterior chamber shallowing
• High risk of acute closure

It does not correct the underlying:

Large, mobile microspherophakic lens.

Why Iridotomy May Not Be Enough

Even after a patent iridotomy, the spherical lens can continue to cause:

• Anterior chamber crowding
• Chronic angle narrowing
• Lens instability

Therefore some patients continue to develop:

Angle-closure glaucoma despite LPI.

When Lens Extraction Becomes Definitive Therapy

Lens removal should be considered for:

• Recurrent or uncontrolled pupillary block
• Progressive angle closure
• Glaucoma inadequately controlled medically
• Significant lens subluxation
• Anterior lens dislocation
• Severe lenticular myopia causing functional impairment

Removing the bulky spherical lens:

Deepens the anterior chamber and removes the principal source of pupillary block.

Surgical Challenges

Lens surgery can be technically difficult because of:

• Weak or abnormal zonules
• Lens mobility
• Small capsular bag
• Vitreous prolapse
• Poor capsular support

Surgery should ideally be performed by an anterior segment surgeon experienced in:

Ectopia lentis and complex lens surgery.

Surgical Options

Depending on age and anatomy, options include:

• Lensectomy
• Pars plana or limbal lens removal
• Anterior vitrectomy when required
• Aphakia
• Secondary IOL implantation

The exact approach depends on:

• Zonular support
• Capsular integrity
• Patient age
• Glaucoma status

Intraocular Lens Decisions

Stable in-the-bag IOL implantation may not be possible when zonular support is poor.

Alternative approaches include:

• Scleral-fixated IOL
• Iris-fixated IOL
• Leaving the patient aphakic with optical rehabilitation

IOL choice must be individualized rather than assumed at the time of lensectomy.

Glaucoma After Lens Removal

Lens extraction often improves angle anatomy, but longstanding disease may leave:

• Peripheral anterior synechiae
• Trabecular damage
• Established optic neuropathy

Some patients therefore continue to require:

• Glaucoma medications
• Glaucoma surgery

after lens removal.

Role of Glaucoma Surgery

If IOP remains uncontrolled despite correction of the lens-related mechanism, options may include:

• Trabeculectomy
• Glaucoma drainage device
• Selected angle surgery

The choice depends on:

• Degree of synechial closure
• Age
• Previous surgery
• Remaining visual potential

Why Supine Positioning Is Not Definitive Therapy

Historical descriptions suggested lying supine or using ocular massage to encourage posterior movement of a dislocated lens.

These measures are:

Temporary at best and not definitive treatment.

An anteriorly dislocated lens with pupillary block or corneal compromise requires urgent ophthalmic surgical management.

Long-Term Surveillance

Patients with an intact lens should undergo lifelong monitoring for:

• Increasing myopia
• Progressive ectopia lentis
• Angle narrowing
• Elevated IOP
• Glaucomatous optic nerve damage

Follow-up frequency depends on:

• Age
• Lens position
• Angle anatomy
• IOP

What Patients Should Know

Patients and families should recognize symptoms of acute angle closure:

• Eye pain
• Redness
• Sudden blurred vision
• Halos
• Headache
• Nausea

They should seek urgent eye care if these occur.

Expected Long-Term Course

Visual prognosis depends largely on:

• Timing of glaucoma recognition
• Degree of lens instability
• Success of surgical correction
• Presence of amblyopia in children

With appropriate surveillance and intervention:

Useful vision can often be preserved.

Major Ocular Complications

Potential complications include:

• Acute angle-closure glaucoma
• Chronic synechial angle closure
• Glaucomatous optic neuropathy
• Lens dislocation
• Corneal endothelial damage
• High refractive error
• Amblyopia

Severe untreated glaucoma can cause irreversible blindness.

High-Yield Takeaways

• Weill-Marchesani syndrome is a rare inherited connective-tissue disorder characterized by microspherophakia, ectopia lentis, lenticular myopia, short stature, brachydactyly, and joint stiffness.
• Both autosomal recessive and autosomal dominant forms occur.
• Important genes include ADAMTS10, FBN1, and LTBP2, with related ADAMTS17-associated phenotypes.
• The hallmark ocular abnormality is microspherophakia: a small-diameter, unusually spherical and thick crystalline lens.
• Microspherophakia causes high lenticular myopia and predisposes strongly to pupillary-block angle closure.
• Angle closure occurs because the spherical lens moves anteriorly, increasing iris-lens contact and producing iris bombé.
• Lens subluxation or complete dislocation can occur because of abnormal zonular support.
• The syndrome contrasts with Marfan disease: WMS causes short stature and brachydactyly, whereas Marfan syndrome causes tall stature and arachnodactyly.
• Gonioscopy and anterior segment imaging help document angle narrowing and the lens-iris relationship.
• Medical glaucoma therapy generally begins with aqueous suppressants.
• Miotics are usually avoided because they may allow further anterior lens movement and worsen pupillary block.
• Mydriasis can also precipitate angle closure in a markedly crowded eye and should be used cautiously.
• Laser peripheral iridotomy can relieve pupillary block, but it does not remove the underlying microspherophakic lens.
• Routine prophylactic iridotomy for every patient is too absolute; it is most appropriate when there is occludable angle anatomy or evidence of pupillary-block risk.
• Lens extraction is definitive therapy for recurrent or uncontrolled angle closure, severe ectopia lentis, anterior lens dislocation, or visually significant lenticular myopia.
• Lens surgery can be difficult because of zonular weakness and capsular instability, and IOL fixation must be individualized.
• Chronic glaucoma may persist even after lens removal because of peripheral anterior synechiae and permanent trabecular damage.
• Children require attention to refractive correction and amblyopia prevention in addition to glaucoma surveillance.
• Lifelong follow-up is essential because both lens instability and glaucoma can progress over time.

High-Yield Takeaways

Ophthalmology – Granulomatosis With Polyangiitis

What the Disease Represents

Granulomatosis with polyangiitis (GPA) is a systemic ANCA-associated necrotizing vasculitis that predominantly affects small- to medium-sized vessels.

The classic organ pattern is:

• Upper respiratory tract
• Lower respiratory tract
• Kidneys

Ocular and orbital disease is also common and may occasionally be the presenting manifestation.

The characteristic pathologic combination is:

Necrotizing granulomatous inflammation + vasculitis + pauci-immune glomerulonephritis.

Important Modern Terminology

The historical term:

Wegener granulomatosis

has been replaced by:

Granulomatosis with polyangiitis (GPA).

This is the preferred modern terminology in clinical practice and classification systems.

Why the Disease Develops

GPA is an autoimmune inflammatory disease involving:

• Activated neutrophils
• Vascular endothelium
• B lymphocytes
• T lymphocytes
• Complement pathways

The antibody most strongly associated with GPA is:

PR3-ANCA

which often produces a classic:

Cytoplasmic ANCA (c-ANCA) pattern.

However, ANCA status alone does not establish or exclude the diagnosis.

ANCA Patterns

The two principal ANCA antigen targets are:

• Proteinase 3 (PR3)
• Myeloperoxidase (MPO)

GPA is most strongly associated with:

PR3-ANCA

whereas microscopic polyangiitis is more frequently associated with MPO-ANCA.

Some patients with GPA are:

ANCA-negative, particularly when disease is localized to the orbit or upper respiratory tract.

Who Typically Develops GPA

GPA can occur at almost any age but most often presents in:

Middle adulthood.

There is no clinically useful strong male predominance.

Disease occurs in all ethnic groups, although incidence and ANCA subtype frequencies vary geographically and by ancestry.

Why Early Recognition Matters

Untreated systemic GPA can cause:

• Rapidly progressive glomerulonephritis
• Pulmonary hemorrhage
• Respiratory failure
• Permanent hearing loss
• Orbital destruction
• Optic neuropathy

Modern immunosuppressive therapy has transformed GPA from a frequently fatal disease into a:

Treatable but relapsing chronic systemic vasculitis.

Upper Airway Disease

ENT involvement is extremely common.

Manifestations include:

• Chronic sinusitis
• Nasal crusting
• Bloody nasal discharge
• Nasal ulceration
• Otitis media
• Conductive or sensorineural hearing loss
• Eustachian tube dysfunction
• Subglottic stenosis

Symptoms may initially resemble recurrent infection.

Saddle-Nose Deformity

Chronic destructive inflammation can damage the:

Nasal septum and supporting cartilage

producing a:

Saddle-nose deformity.

This is a classic late manifestation but should not be required for diagnosis.

Strawberry Gingivitis

A highly characteristic but uncommon oral finding is:

“Strawberry gingivitis.”

The gingiva becomes:

• Red
• Friable
• Granular
• Hyperplastic

Its presence can be a strong diagnostic clue.

Pulmonary Involvement

Pulmonary GPA may cause:

• Nodules
• Cavitary nodules
• Pulmonary infiltrates
• Cough
• Dyspnea
• Hemoptysis

A particularly severe manifestation is:

Diffuse alveolar hemorrhage.

Renal Disease

The typical renal lesion is:

Pauci-immune necrotizing crescentic glomerulonephritis.

Clinical clues include:

• Hematuria
• Dysmorphic erythrocytes
• Red-cell casts
• Proteinuria
• Rising creatinine

Renal disease may initially be:

Clinically silent.

Urinalysis and renal function testing are therefore essential even when the patient has no urinary symptoms.

Ocular Disease Can Be the First Manifestation

Eye or orbital disease may precede the systemic diagnosis.

Important ophthalmic manifestations include:

• Scleritis
• Peripheral ulcerative keratitis
• Episcleritis
• Orbital inflammatory disease
• Nasolacrimal obstruction
• Uveitis
• Retinal vasculitis
• Retinal vascular occlusion
• Optic neuropathy

Almost any ocular structure can be affected.

Scleritis

One of the most important ocular manifestations is:

Anterior or posterior scleritis.

Patients may develop:

• Deep severe ocular pain
• Violaceous scleral injection
• Tenderness
• Pain with eye movement

The most dangerous form is:

Necrotizing scleritis.

This signals potentially severe systemic vasculitis and requires urgent systemic therapy.

Peripheral Ulcerative Keratitis

Peripheral ulcerative keratitis (PUK) is another sight-threatening manifestation.

Typical findings include:

• Peripheral stromal thinning
• Epithelial defect
• Adjacent conjunctival inflammation
• Progressive corneal melt

Severe disease can progress to:

Descemetocele or perforation.

Why PUK Is a Systemic Emergency

GPA-associated PUK reflects active systemic immune-mediated vasculitis rather than simply local corneal disease.

Treatment therefore requires:

Systemic immunosuppression.

Topical treatment alone is inadequate.

Important Rule Before Treating Corneal Melt

Before escalating immunosuppression in PUK:

Exclude infectious keratitis.

Microbial infection can mimic or complicate autoimmune corneal ulceration.

Episcleritis

Episcleritis can occur and is generally less dangerous than scleritis.

It typically causes:

• Mild discomfort
• Sectoral redness
• Superficial vessels

Unlike scleritis, it is usually not associated with severe deep pain.

Orbital GPA

Orbital inflammation may result from:

• Direct granulomatous orbital disease
• Extension from adjacent sinus disease

Possible manifestations include:

• Proptosis
• Orbital pain
• Diplopia
• Restricted motility
• Eyelid edema
• Orbital mass-like inflammation

Why Orbital GPA Can Threaten Vision

Inflammatory tissue may compress:

• Optic nerve
• Orbital apex
• Extraocular muscles

This can produce:

Compressive optic neuropathy.

Red flags include:

• Reduced visual acuity
• Dyschromatopsia
• RAPD
• Visual-field loss

These require urgent systemic treatment and sometimes surgical decompression.

Nasolacrimal Obstruction

Chronic sinonasal and peri-lacrimal inflammation may scar the:

Nasolacrimal drainage system.

Patients may develop:

• Epiphora
• Recurrent dacryocystitis

Definitive lacrimal surgery is generally best performed once systemic inflammation is adequately controlled.

Uveitis

Anterior, intermediate, posterior, or panuveitis may occur but is less characteristic than:

• Scleritis
• PUK
• Orbital disease

When uveitis is present, search carefully for other systemic evidence of GPA.

Retinal Vasculitis

Retinal involvement may include:

• Retinal vasculitis
• Cotton-wool spots
• Retinal hemorrhage
• Arterial occlusion
• Venous occlusion
• Retinal ischemia

Vision may be permanently reduced when the:

• Macula
• Optic nerve
• Major retinal vessels

are affected.

Optic Nerve Disease

Optic neuropathy may result from:

• Orbital compression
• Vasculitic ischemia
• Contiguous inflammation
• Rare direct granulomatous infiltration

Rapidly declining vision in a patient with orbital GPA is an:

Emergency.

Neurologic Manifestations

GPA may cause:

• Mononeuritis multiplex
• Peripheral neuropathy
• Cranial neuropathies
• Pachymeningitis
• Stroke
• Rare cerebral granulomatous disease

Headache with cranial neuropathies may warrant:

Contrast-enhanced MRI.

Skin Manifestations

Skin disease may include:

• Palpable purpura
• Petechiae
• Nodules
• Ulcers
• Vesicles
• Pustules
• Digital ischemia

Lower extremities are frequently affected.

Establishing the Diagnosis

Diagnosis integrates:

• Clinical phenotype
• ANCA testing
• Urinalysis
• Renal function
• Imaging
• Histopathology when needed

No single test should be interpreted in isolation.

ANCA Testing

Modern testing generally measures:

• PR3-ANCA
• MPO-ANCA

rather than relying solely on immunofluorescence patterns such as c-ANCA or p-ANCA.

A positive PR3-ANCA in a compatible clinical setting strongly supports GPA.

Important Limitation of ANCA

A negative ANCA result does:

Not exclude GPA.

ANCA-negative disease is particularly possible in:

• Localized orbital disease
• Limited ENT disease

Clinical suspicion and biopsy may still be necessary.

Urinalysis and Renal Testing

Initial evaluation should usually include:

• Serum creatinine
• Urinalysis
• Urine protein assessment

Look for:

• Hematuria
• Proteinuria
• Red-cell casts

These may reveal occult renal involvement that immediately changes treatment intensity.

Inflammatory Markers

Useful supportive tests include:

• CRP
• ESR
• CBC

Possible findings include:

• Anemia
• Leukocytosis
• Thrombocytosis

These are nonspecific.

Chest Imaging

CT of the chest is more sensitive than plain radiography for detecting:

• Pulmonary nodules
• Cavitation
• Ground-glass opacity
• Pulmonary hemorrhage

Chest imaging is often warranted even when respiratory symptoms are relatively mild.

Sinonasal Imaging

CT of the sinuses may reveal:

• Mucosal thickening
• Chronic opacification
• Bony erosion
• Septal destruction
• Sclerosing changes

These findings can help define:

Extent of destructive ENT disease.

Orbital Imaging

For suspected orbital involvement:

Contrast-enhanced MRI or CT of the orbits and sinuses

can identify:

• Orbital inflammatory masses
• Extraocular muscle involvement
• Optic nerve compression
• Contiguous sinus disease
• Bone destruction

MRI is particularly useful for:

Orbital apex and soft-tissue disease.

Role of Biopsy

Histopathology is useful when:

• Diagnosis is uncertain
• ANCA is negative
• Malignancy or infection remains possible
• Tissue confirmation will alter treatment

Potential biopsy sites include:

• Kidney
• Lung
• Nasal or sinus tissue
• Skin
• Orbit

Renal Biopsy

Renal biopsy classically shows:

Pauci-immune necrotizing crescentic glomerulonephritis.

“Pauci-immune” means there is little or no immunoglobulin deposition on immunofluorescence.

Histopathology of Granulomatous Disease

Characteristic findings can include:

• Necrotizing vasculitis
• Geographic necrosis
• Granulomatous inflammation
• Multinucleated giant cells

Not every biopsy contains the complete classic triad.

Major Diagnostic Alternatives

Important mimics include:

• Microscopic polyangiitis
• Eosinophilic granulomatosis with polyangiitis
• Anti-GBM disease
• Sarcoidosis
• IgG4-related disease
• Relapsing polychondritis
• Systemic lupus erythematosus
• Tuberculosis
• Fungal infection
• Lymphoma

Cocaine-Associated Midline Destruction

Intranasal cocaine, especially when contaminated with levamisole, can cause:

• Destructive sinonasal lesions
• ANCA positivity
• Vasculitic findings

This can closely resemble GPA.

A careful substance-use history may therefore be diagnostically important.

GPA vs Microscopic Polyangiitis

Both are ANCA-associated vasculitides.

GPA

Characteristically has:

• Granulomatous inflammation
• Destructive ENT disease
• Pulmonary nodules
• PR3-ANCA more commonly

Microscopic Polyangiitis

Typically lacks:

• Granulomatous inflammation
• Destructive upper-airway disease

and is more often associated with:

MPO-ANCA.

GPA vs Eosinophilic Granulomatosis With Polyangiitis

EGPA is suggested by:

• Asthma
• Marked eosinophilia
• Chronic eosinophilic airway disease

These are not typical dominant features of GPA.

The Modern Treatment Framework

Treatment is divided into:

1. Induction of remission
2. Maintenance of remission

Choice depends on whether disease is:

• Organ-threatening
• Life-threatening
• Non–organ-threatening

Organ- or Life-Threatening Disease

Examples include:

• Rapidly progressive glomerulonephritis
• Diffuse alveolar hemorrhage
• Necrotizing scleritis
• Severe PUK
• Orbital compression threatening the optic nerve
• CNS vasculitis

These generally require:

Rapid systemic induction therapy.

First-Line Induction Therapy

Modern induction usually combines:

Glucocorticoids + rituximab or cyclophosphamide.

For many patients:

Rituximab is preferred, particularly in relapsing disease or when avoidance of cyclophosphamide toxicity is desirable.

Rituximab

Rituximab is an anti-CD20 monoclonal antibody that depletes B cells.

It is effective for:

• Newly diagnosed severe GPA
• Relapsing GPA
• Maintenance therapy

It has largely replaced prolonged oral cyclophosphamide in many treatment strategies.

Cyclophosphamide

Cyclophosphamide remains highly effective for severe disease.

Potential toxicities include:

• Myelosuppression
• Serious infection
• Hemorrhagic cystitis
• Infertility
• Bladder cancer
• Other malignancies

Modern treatment generally limits cumulative exposure whenever possible.

Glucocorticoid Strategy

High-dose systemic corticosteroids are commonly used during induction.

Depending on disease severity, treatment may begin with:

• Oral prednisone/prednisolone
• IV methylprednisolone pulses for immediately threatening disease

Modern protocols increasingly favor:

Reduced cumulative glucocorticoid exposure

because prolonged high-dose therapy causes substantial toxicity.

Avacopan

A major modern development is:

Avacopan, an oral complement C5a receptor inhibitor.

It can be used in selected patients with severe ANCA-associated vasculitis as part of a regimen with:

• Rituximab

or:

• Cyclophosphamide-based therapy

Its principal role is to reduce dependence on prolonged high-dose glucocorticoids.

Non–Organ-Threatening Disease

Selected milder disease may be treated with:

• Glucocorticoids
• Methotrexate

depending on:

• Renal function
• Extent of disease
• Systemic involvement

Methotrexate is not appropriate for severe renal failure or immediately life-threatening disease.

Maintenance of Remission

Once remission is induced, maintenance options include:

• Rituximab
• Azathioprine
• Methotrexate
• Mycophenolate mofetil in selected patients

Rituximab has become a particularly important maintenance agent because it reduces relapse risk in many patients.

Why Cyclophosphamide Is Not Used Long Term

Older protocols often continued cyclophosphamide for many months.

Modern practice attempts to transition away from it once remission is achieved because cumulative toxicity rises with:

Duration and total dose.

Pneumocystis Prophylaxis

Patients receiving substantial immunosuppression, especially:

• Rituximab
• Cyclophosphamide
• High-dose corticosteroids

often require prophylaxis against:

Pneumocystis jirovecii pneumonia (PJP).

A common agent is:

Trimethoprim-sulfamethoxazole.

Important Correction About TMP-SMX

TMP-SMX should not be viewed as routine primary treatment for systemic GPA.

Its major modern role is:

PJP prophylaxis

although older studies suggested possible reduction of ENT relapse in selected patients.

It does not replace disease-modifying immunosuppression.

Plasma Exchange – Important Modern Correction

Older teaching frequently recommended plasmapheresis for:

• Severe renal disease
• Pulmonary hemorrhage

Modern evidence has substantially narrowed its routine use.

Plasma exchange is not automatically indicated for all patients with pulmonary hemorrhage or severe ANCA vasculitis.

It may still be considered in selected situations such as:

• Very severe rapidly progressive renal failure
• High risk of dialysis dependence
• Concomitant anti-GBM antibodies
• Exceptional life-threatening circumstances

Decisions are individualized with nephrology/rheumatology.

Treating GPA-Associated Scleritis

Sight-threatening scleritis requires:

Systemic control of the vasculitis.

Treatment may include:

• Systemic corticosteroid
• Rituximab
• Cyclophosphamide
• Other immunomodulatory therapy during maintenance

Topical treatment alone is inadequate for severe GPA scleritis.

Treating Peripheral Ulcerative Keratitis

Management includes:

• Urgent systemic immunosuppression
• Intensive lubrication
• Treatment of associated surface disease

For impending or actual perforation, structural measures may include:

• Cyanoacrylate glue
• Bandage contact lens
• Amniotic membrane
• Lamellar or penetrating keratoplasty in selected cases

The systemic vasculitis must still be controlled.

Orbital Disease Management

Active orbital GPA generally requires:

Systemic immunosuppression.

If progressive proptosis causes:

• Optic nerve compression
• Exposure keratopathy
• Severe structural compromise

urgent orbital decompression or biopsy may be required.

Surgery alone does not control the underlying vasculitis.

Surgical Timing in Quiescent Disease

Reconstructive procedures for:

• Nasolacrimal obstruction
• Saddle-nose deformity
• Eyelid abnormalities

are generally best performed after inflammatory disease has been:

Stably controlled.

Monitoring Treatment Safety

Depending on therapy, monitoring may include:

• CBC
• Creatinine
• Liver function
• Urinalysis
• Immunoglobulin levels with repeated rituximab
• Infection screening

Cyclophosphamide requires particular attention to:

• Cytopenia
• Hematuria
• Bladder toxicity

Fertility Considerations

Cyclophosphamide can cause:

Gonadal toxicity and infertility.

For younger patients, fertility preservation should be considered before substantial exposure when circumstances allow.

Bone Protection During Steroid Therapy

Patients receiving prolonged systemic glucocorticoids should undergo individualized:

• Fracture-risk assessment
• Calcium/vitamin D optimization
• Bone-density assessment when indicated
• Pharmacologic osteoporosis prophylaxis when risk warrants

Routine calcium alone is not sufficient management for every patient.

Why ANCA Titers Should Not Dictate Treatment Alone

Serial PR3-ANCA levels may correlate imperfectly with disease activity.

A rising ANCA level does:

Not by itself prove relapse.

Treatment decisions should be based primarily on:

• Clinical findings
• Organ involvement
• Laboratory evidence of active disease
• Imaging when appropriate

Follow-Up Strategy

Long-term follow-up generally involves:

• Rheumatology
• Nephrology when renal disease is present
• Pulmonology when lung disease is significant
• ENT
• Ophthalmology for ocular involvement

Patients remain at risk of:

Relapse even after prolonged remission.

Relapse

Relapses are relatively common, particularly in:

PR3-ANCA–positive GPA.

Recurrence may involve:

• Same organ system
• Different organ system

A patient previously treated for GPA who develops new:

• Eye pain
• Hematuria
• Sinus disease
• Pulmonary symptoms

requires prompt reassessment.

Expected Long-Term Course

Modern therapy allows many patients to achieve durable remission.

However, morbidity may result from:

• Recurrent vasculitis
• Chronic renal impairment
• Airway stenosis
• Hearing loss
• Structural ENT damage
• Ocular injury
• Immunosuppressive toxicity

Long-term management therefore balances:

Relapse prevention against treatment toxicity.

Major Causes of Ocular Visual Loss

Permanent visual impairment may result from:

• Necrotizing scleritis
• Corneal perforation from PUK
• Compressive optic neuropathy
• Retinal artery occlusion
• Retinal vasculitis
• Severe orbital inflammation
• Secondary glaucoma

Early systemic diagnosis can be vision-saving as well as life-saving.

High-Yield Takeaways

• Granulomatosis with polyangiitis is the modern name for Wegener granulomatosis.
• GPA is an ANCA-associated necrotizing granulomatous vasculitis affecting mainly the upper airway, lungs, kidneys, and eyes.
• The antibody most strongly associated with GPA is PR3-ANCA, often producing a c-ANCA pattern.
• Negative ANCA does not exclude GPA, particularly in localized orbital or ENT disease.
• Classic systemic manifestations include destructive sinus disease, pulmonary nodules or hemorrhage, and pauci-immune crescentic glomerulonephritis.
• Urinalysis is essential because significant renal vasculitis can be asymptomatic initially.
• Important ophthalmic manifestations include scleritis, peripheral ulcerative keratitis, orbital inflammation, nasolacrimal obstruction, retinal vasculitis, and optic neuropathy.
• Necrotizing scleritis and PUK are sight-threatening manifestations of systemic vasculitis and require systemic immunosuppression.
• Orbital disease can produce compressive optic neuropathy; falling acuity, dyschromatopsia, or RAPD requires urgent assessment.
• PR3-ANCA/MPO-ANCA testing is preferred over relying exclusively on c-ANCA/p-ANCA staining patterns.
• Biopsy may demonstrate necrotizing granulomatous vasculitis, while renal biopsy classically shows pauci-immune necrotizing crescentic glomerulonephritis.
• Important mimics include microscopic polyangiitis, EGPA, anti-GBM disease, sarcoidosis, IgG4-related disease, infection, lymphoma, and cocaine-associated destructive sinonasal disease.
• Modern induction of severe GPA generally uses glucocorticoids plus rituximab or cyclophosphamide.
• Rituximab is now a major first-line agent and is particularly useful in relapsing disease.
• Avacopan can reduce glucocorticoid exposure in selected patients with severe ANCA-associated vasculitis.
• Cyclophosphamide remains effective but should be limited because of infection, infertility, marrow toxicity, hemorrhagic cystitis, and malignancy risk.
• Maintenance commonly uses rituximab, azathioprine, or methotrexate, depending on the patient.
• TMP-SMX is important primarily for Pneumocystis prophylaxis during substantial immunosuppression, not as definitive treatment for systemic GPA.
• Plasma exchange is no longer routinely used for every case of pulmonary hemorrhage or severe renal GPA; it is reserved for selected high-risk situations.
• ANCA titers should not be used alone to diagnose relapse or dictate therapy.
• With early diagnosis and modern immunosuppressive treatment, long-term survival is dramatically better than in the pre-treatment era, but lifelong surveillance for relapse and treatment toxicity is essential.

High-Yield Takeaways

Important Modern Terminology The historical term: Wegener granulomatosis has been replaced by: Granulomatosis with polyangiitis (GPA). This is the preferred modern terminology in clinical practice and classification systems.

Why the Disease Develops GPA is an autoimmune inflammatory disease involving:  Activated neutrophils Vascular endothelium B lymphocytes T lymphocytes Complement pathways  The antibody most strongly associated with GPA is: PR3-ANCA which often produces a classic: Cytoplasmic ANCA (c-ANCA) pattern. However, ANCA status alone does not establish or exclude the diagnosis.

ANCA Patterns The two principal ANCA antigen targets are:  Proteinase 3 (PR3) Myeloperoxidase (MPO)  GPA is most strongly associated with: PR3-ANCA whereas microscopic polyangiitis is more frequently associated with MPO-ANCA. Some patients with GPA are: ANCA-negative, particularly when disease is localized to the orbit or upper respiratory tract.

Who Typically Develops GPA GPA can occur at almost any age but most often presents in: Middle adulthood. There is no clinically useful strong male predominance. Disease occurs in all ethnic groups, although incidence and ANCA subtype frequencies vary geographically and by ancestry.

Why Early Recognition Matters Untreated systemic GPA can cause:  Rapidly progressive glomerulonephritis Pulmonary hemorrhage Respiratory failure Permanent hearing loss Orbital destruction Optic neuropathy  Modern immunosuppressive therapy has transformed GPA from a frequently fatal disease into a: Treatable but relapsing chronic systemic vasculitis.

Upper Airway Disease ENT involvement is extremely common. Manifestations include:  Chronic sinusitis Nasal crusting Bloody nasal discharge Nasal ulceration Otitis media Conductive or sensorineural hearing loss Eustachian tube dysfunction Subglottic stenosis  Symptoms may initially resemble recurrent infection.

Saddle-Nose Deformity Chronic destructive inflammation can damage the: Nasal septum and supporting cartilage producing a: Saddle-nose deformity. This is a classic late manifestation but should not be required for diagnosis.

Strawberry Gingivitis A highly characteristic but uncommon oral finding is: “Strawberry gingivitis.” The gingiva becomes:  Red Friable Granular Hyperplastic  Its presence can be a strong diagnostic clue.

Pulmonary Involvement Pulmonary GPA may cause:  Nodules Cavitary nodules Pulmonary infiltrates Cough Dyspnea Hemoptysis  A particularly severe manifestation is: Diffuse alveolar hemorrhage.

Renal Disease The typical renal lesion is: Pauci-immune necrotizing crescentic glomerulonephritis. Clinical clues include:  Hematuria Dysmorphic erythrocytes Red-cell casts Proteinuria Rising creatinine  Renal disease may initially be: Clinically silent. Urinalysis and renal function testing are therefore essential even when the patient has no urinary symptoms.

Ocular Disease Can Be the First Manifestation Eye or orbital disease may precede the systemic diagnosis. Important ophthalmic manifestations include:  Scleritis Peripheral ulcerative keratitis Episcleritis Orbital inflammatory disease Nasolacrimal obstruction Uveitis Retinal vasculitis Retinal vascular occlusion Optic neuropathy  Almost any ocular structure can be affected.

Scleritis One of the most important ocular manifestations is: Anterior or posterior scleritis. Patients may develop:  Deep severe ocular pain Violaceous scleral injection Tenderness Pain with eye movement  The most dangerous form is: Necrotizing scleritis. This signals potentially severe systemic vasculitis and requires urgent systemic therapy.

Peripheral Ulcerative Keratitis Peripheral ulcerative keratitis (PUK) is another sight-threatening manifestation. Typical findings include:  Peripheral stromal thinning Epithelial defect Adjacent conjunctival inflammation Progressive corneal melt  Severe disease can progress to: Descemetocele or perforation.

Why PUK Is a Systemic Emergency GPA-associated PUK reflects active systemic immune-mediated vasculitis rather than simply local corneal disease. Treatment therefore requires: Systemic immunosuppression. Topical treatment alone is inadequate.

Important Rule Before Treating Corneal Melt Before escalating immunosuppression in PUK: Exclude infectious keratitis. Microbial infection can mimic or complicate autoimmune corneal ulceration.

Episcleritis Episcleritis can occur and is generally less dangerous than scleritis. It typically causes:  Mild discomfort Sectoral redness Superficial vessels  Unlike scleritis, it is usually not associated with severe deep pain.

Orbital GPA Orbital inflammation may result from:  Direct granulomatous orbital disease Extension from adjacent sinus disease  Possible manifestations include:  Proptosis Orbital pain Diplopia Restricted motility Eyelid edema Orbital mass-like inflammation

Why Orbital GPA Can Threaten Vision Inflammatory tissue may compress:  Optic nerve Orbital apex Extraocular muscles  This can produce: Compressive optic neuropathy. Red flags include:  Reduced visual acuity Dyschromatopsia RAPD Visual-field loss  These require urgent systemic treatment and sometimes surgical decompression.

Nasolacrimal Obstruction Chronic sinonasal and peri-lacrimal inflammation may scar the: Nasolacrimal drainage system. Patients may develop:  Epiphora Recurrent dacryocystitis  Definitive lacrimal surgery is generally best performed once systemic inflammation is adequately controlled.

Uveitis Anterior, intermediate, posterior, or panuveitis may occur but is less characteristic than:  Scleritis PUK Orbital disease  When uveitis is present, search carefully for other systemic evidence of GPA.

Retinal Vasculitis Retinal involvement may include:  Retinal vasculitis Cotton-wool spots Retinal hemorrhage Arterial occlusion Venous occlusion Retinal ischemia  Vision may be permanently reduced when the:  Macula Optic nerve Major retinal vessels  are affected.

Optic Nerve Disease Optic neuropathy may result from:  Orbital compression Vasculitic ischemia Contiguous inflammation Rare direct granulomatous infiltration  Rapidly declining vision in a patient with orbital GPA is an: Emergency.

Neurologic Manifestations GPA may cause:  Mononeuritis multiplex Peripheral neuropathy Cranial neuropathies Pachymeningitis Stroke Rare cerebral granulomatous disease  Headache with cranial neuropathies may warrant: Contrast-enhanced MRI.

Skin Manifestations Skin disease may include:  Palpable purpura Petechiae Nodules Ulcers Vesicles Pustules Digital ischemia  Lower extremities are frequently affected.

Establishing the Diagnosis Diagnosis integrates:  Clinical phenotype ANCA testing Urinalysis Renal function Imaging Histopathology when needed  No single test should be interpreted in isolation.

ANCA Testing Modern testing generally measures:  PR3-ANCA MPO-ANCA  rather than relying solely on immunofluorescence patterns such as c-ANCA or p-ANCA. A positive PR3-ANCA in a compatible clinical setting strongly supports GPA.

Important Limitation of ANCA A negative ANCA result does: Not exclude GPA. ANCA-negative disease is particularly possible in:  Localized orbital disease Limited ENT disease  Clinical suspicion and biopsy may still be necessary.

Urinalysis and Renal Testing Initial evaluation should usually include:  Serum creatinine Urinalysis Urine protein assessment  Look for:  Hematuria Proteinuria Red-cell casts  These may reveal occult renal involvement that immediately changes treatment intensity.

Inflammatory Markers Useful supportive tests include:  CRP ESR CBC  Possible findings include:  Anemia Leukocytosis Thrombocytosis  These are nonspecific.

Chest Imaging CT of the chest is more sensitive than plain radiography for detecting:  Pulmonary nodules Cavitation Ground-glass opacity Pulmonary hemorrhage  Chest imaging is often warranted even when respiratory symptoms are relatively mild.

Sinonasal Imaging CT of the sinuses may reveal:  Mucosal thickening Chronic opacification Bony erosion Septal destruction Sclerosing changes  These findings can help define: Extent of destructive ENT disease.

Orbital Imaging For suspected orbital involvement: Contrast-enhanced MRI or CT of the orbits and sinuses can identify:  Orbital inflammatory masses Extraocular muscle involvement Optic nerve compression Contiguous sinus disease Bone destruction  MRI is particularly useful for: Orbital apex and soft-tissue disease.

Role of Biopsy Histopathology is useful when:  Diagnosis is uncertain ANCA is negative Malignancy or infection remains possible Tissue confirmation will alter treatment  Potential biopsy sites include:  Kidney Lung Nasal or sinus tissue Skin Orbit

Renal Biopsy Renal biopsy classically shows: Pauci-immune necrotizing crescentic glomerulonephritis. “Pauci-immune” means there is little or no immunoglobulin deposition on immunofluorescence.

Histopathology of Granulomatous Disease Characteristic findings can include:  Necrotizing vasculitis Geographic necrosis Granulomatous inflammation Multinucleated giant cells  Not every biopsy contains the complete classic triad.

Major Diagnostic Alternatives Important mimics include:  Microscopic polyangiitis Eosinophilic granulomatosis with polyangiitis Anti-GBM disease Sarcoidosis IgG4-related disease Relapsing polychondritis Systemic lupus erythematosus Tuberculosis Fungal infection Lymphoma

Cocaine-Associated Midline Destruction Intranasal cocaine, especially when contaminated with levamisole, can cause:  Destructive sinonasal lesions ANCA positivity Vasculitic findings  This can closely resemble GPA. A careful substance-use history may therefore be diagnostically important.

GPA vs Microscopic Polyangiitis Both are ANCA-associated vasculitides. GPA Characteristically has:  Granulomatous inflammation Destructive ENT disease Pulmonary nodules PR3-ANCA more commonly  Microscopic Polyangiitis Typically lacks:  Granulomatous inflammation Destructive upper-airway disease  and is more often associated with: MPO-ANCA.

GPA vs Eosinophilic Granulomatosis With Polyangiitis EGPA is suggested by:  Asthma Marked eosinophilia Chronic eosinophilic airway disease  These are not typical dominant features of GPA.

The Modern Treatment Framework Treatment is divided into:  Induction of remission Maintenance of remission  Choice depends on whether disease is:  Organ-threatening Life-threatening Non–organ-threatening

Organ- or Life-Threatening Disease Examples include:  Rapidly progressive glomerulonephritis Diffuse alveolar hemorrhage Necrotizing scleritis Severe PUK Orbital compression threatening the optic nerve CNS vasculitis  These generally require: Rapid systemic induction therapy.

First-Line Induction Therapy Modern induction usually combines: Glucocorticoids + rituximab or cyclophosphamide. For many patients: Rituximab is preferred, particularly in relapsing disease or when avoidance of cyclophosphamide toxicity is desirable.

Rituximab Rituximab is an anti-CD20 monoclonal antibody that depletes B cells. It is effective for:  Newly diagnosed severe GPA Relapsing GPA Maintenance therapy  It has largely replaced prolonged oral cyclophosphamide in many treatment strategies.

Cyclophosphamide Cyclophosphamide remains highly effective for severe disease. Potential toxicities include:  Myelosuppression Serious infection Hemorrhagic cystitis Infertility Bladder cancer Other malignancies  Modern treatment generally limits cumulative exposure whenever possible.

Glucocorticoid Strategy High-dose systemic corticosteroids are commonly used during induction. Depending on disease severity, treatment may begin with:  Oral prednisone/prednisolone IV methylprednisolone pulses for immediately threatening disease  Modern protocols increasingly favor: Reduced cumulative glucocorticoid exposure because prolonged high-dose therapy causes substantial toxicity.

Avacopan A major modern development is: Avacopan, an oral complement C5a receptor inhibitor. It can be used in selected patients with severe ANCA-associated vasculitis as part of a regimen with:  Rituximab  or:  Cyclophosphamide-based therapy  Its principal role is to reduce dependence on prolonged high-dose glucocorticoids.

Non–Organ-Threatening Disease Selected milder disease may be treated with:  Glucocorticoids Methotrexate  depending on:  Renal function Extent of disease Systemic involvement  Methotrexate is not appropriate for severe renal failure or immediately life-threatening disease.

Maintenance of Remission Once remission is induced, maintenance options include:  Rituximab Azathioprine Methotrexate Mycophenolate mofetil in selected patients  Rituximab has become a particularly important maintenance agent because it reduces relapse risk in many patients.

Why Cyclophosphamide Is Not Used Long Term Older protocols often continued cyclophosphamide for many months. Modern practice attempts to transition away from it once remission is achieved because cumulative toxicity rises with: Duration and total dose.

Pneumocystis Prophylaxis Patients receiving substantial immunosuppression, especially:  Rituximab Cyclophosphamide High-dose corticosteroids  often require prophylaxis against: Pneumocystis jirovecii pneumonia (PJP). A common agent is: Trimethoprim-sulfamethoxazole.

Important Correction About TMP-SMX TMP-SMX should not be viewed as routine primary treatment for systemic GPA. Its major modern role is: PJP prophylaxis although older studies suggested possible reduction of ENT relapse in selected patients. It does not replace disease-modifying immunosuppression.

Plasma Exchange – Important Modern Correction Older teaching frequently recommended plasmapheresis for:  Severe renal disease Pulmonary hemorrhage  Modern evidence has substantially narrowed its routine use. Plasma exchange is not automatically indicated for all patients with pulmonary hemorrhage or severe ANCA vasculitis. It may still be considered in selected situations such as:  Very severe rapidly progressive renal failure High risk of dialysis dependence Concomitant anti-GBM antibodies Exceptional life-threatening circumstances  Decisions are individualized with nephrology/rheumatology.

Treating GPA-Associated Scleritis Sight-threatening scleritis requires: Systemic control of the vasculitis. Treatment may include:  Systemic corticosteroid Rituximab Cyclophosphamide Other immunomodulatory therapy during maintenance  Topical treatment alone is inadequate for severe GPA scleritis.

Treating Peripheral Ulcerative Keratitis Management includes:  Urgent systemic immunosuppression Intensive lubrication Treatment of associated surface disease  For impending or actual perforation, structural measures may include:  Cyanoacrylate glue Bandage contact lens Amniotic membrane Lamellar or penetrating keratoplasty in selected cases  The systemic vasculitis must still be controlled.

Orbital Disease Management Active orbital GPA generally requires: Systemic immunosuppression. If progressive proptosis causes:  Optic nerve compression Exposure keratopathy Severe structural compromise  urgent orbital decompression or biopsy may be required. Surgery alone does not control the underlying vasculitis.

Surgical Timing in Quiescent Disease Reconstructive procedures for:  Nasolacrimal obstruction Saddle-nose deformity Eyelid abnormalities  are generally best performed after inflammatory disease has been: Stably controlled.

Monitoring Treatment Safety Depending on therapy, monitoring may include:  CBC Creatinine Liver function Urinalysis Immunoglobulin levels with repeated rituximab Infection screening  Cyclophosphamide requires particular attention to:  Cytopenia Hematuria Bladder toxicity

Fertility Considerations Cyclophosphamide can cause: Gonadal toxicity and infertility. For younger patients, fertility preservation should be considered before substantial exposure when circumstances allow.

Bone Protection During Steroid Therapy Patients receiving prolonged systemic glucocorticoids should undergo individualized:  Fracture-risk assessment Calcium/vitamin D optimization Bone-density assessment when indicated Pharmacologic osteoporosis prophylaxis when risk warrants  Routine calcium alone is not sufficient management for every patient.

Why ANCA Titers Should Not Dictate Treatment Alone Serial PR3-ANCA levels may correlate imperfectly with disease activity. A rising ANCA level does: Not by itself prove relapse. Treatment decisions should be based primarily on:  Clinical findings Organ involvement Laboratory evidence of active disease Imaging when appropriate

Follow-Up Strategy Long-term follow-up generally involves:  Rheumatology Nephrology when renal disease is present Pulmonology when lung disease is significant ENT Ophthalmology for ocular involvement  Patients remain at risk of: Relapse even after prolonged remission.

Relapse Relapses are relatively common, particularly in: PR3-ANCA–positive GPA. Recurrence may involve:  Same organ system Different organ system  A patient previously treated for GPA who develops new:  Eye pain Hematuria Sinus disease Pulmonary symptoms  requires prompt reassessment.

Expected Long-Term Course Modern therapy allows many patients to achieve durable remission. However, morbidity may result from:  Recurrent vasculitis Chronic renal impairment Airway stenosis Hearing loss Structural ENT damage Ocular injury Immunosuppressive toxicity  Long-term management therefore balances: Relapse prevention against treatment toxicity.

Major Causes of Ocular Visual Loss Permanent visual impairment may result from:  Necrotizing scleritis Corneal perforation from PUK Compressive optic neuropathy Retinal artery occlusion Retinal vasculitis Severe orbital inflammation Secondary glaucoma  Early systemic diagnosis can be vision-saving as well as life-saving.

High-Yield Takeaways  Granulomatosis with polyangiitis is the modern name for Wegener granulomatosis. GPA is an ANCA-associated necrotizing granulomatous vasculitis affecting mainly the upper airway, lungs, kidneys, and eyes. The antibody most strongly associated with GPA is PR3-ANCA, often producing a c-ANCA pattern. Negative ANCA does not exclude GPA, particularly in localized orbital or ENT disease. Classic systemic manifestations include destructive sinus disease, pulmonary nodules or hemorrhage, and pauci-immune crescentic glomerulonephritis. Urinalysis is essential because significant renal vasculitis can be asymptomatic initially. Important ophthalmic manifestations include scleritis, peripheral ulcerative keratitis, orbital inflammation, nasolacrimal obstruction, retinal vasculitis, and optic neuropathy. Necrotizing scleritis and PUK are sight-threatening manifestations of systemic vasculitis and require systemic immunosuppression. Orbital disease can produce compressive optic neuropathy; falling acuity, dyschromatopsia, or RAPD requires urgent assessment. PR3-ANCA/MPO-ANCA testing is preferred over relying exclusively on c-ANCA/p-ANCA staining patterns. Biopsy may demonstrate necrotizing granulomatous vasculitis, while renal biopsy classically shows pauci-immune necrotizing crescentic glomerulonephritis. Important mimics include microscopic polyangiitis, EGPA, anti-GBM disease, sarcoidosis, IgG4-related disease, infection, lymphoma, and cocaine-associated destructive sinonasal disease. Modern induction of severe GPA generally uses glucocorticoids plus rituximab or cyclophosphamide. Rituximab is now a major first-line agent and is particularly useful in relapsing disease. Avacopan can reduce glucocorticoid exposure in selected patients with severe ANCA-associated vasculitis. Cyclophosphamide remains effective but should be limited because of infection, infertility, marrow toxicity, hemorrhagic cystitis, and malignancy risk. Maintenance commonly uses rituximab, azathioprine, or methotrexate, depending on the patient. TMP-SMX is important primarily for Pneumocystis prophylaxis during substantial immunosuppression, not as definitive treatment for systemic GPA. Plasma exchange is no longer routinely used for every case of pulmonary hemorrhage or severe renal GPA; it is reserved for selected high-risk situations. ANCA titers should not be used alone to diagnose relapse or dictate therapy. With early diagnosis and modern immunosuppressive treatment, long-term survival is dramatically better than in the pre-treatment era, but lifelong surveillance for relapse and treatment toxicity is essential.  High-Yield Takeaways

Ophthalmology – Vitreoretinal Lymphoma

What the Disorder Represents

Vitreoretinal lymphoma (VRL) is an aggressive lymphoid malignancy involving the:

• Vitreous
• Retina
• Subretinal space
• Retinal pigment epithelium (RPE)

Most primary cases are:

Diffuse large B-cell lymphoma (DLBCL)

and are closely related biologically to primary central nervous system lymphoma (PCNSL).

The preferred term is:

Primary vitreoretinal lymphoma (PVRL)

when the disease arises within the eye/CNS compartment rather than representing secondary spread from systemic lymphoma.

Why “Primary Intraocular Lymphoma” Is Less Precise

The older term:

Primary intraocular lymphoma

is potentially confusing because several distinct lymphomas can occur inside the eye.

These include:

• Primary vitreoretinal lymphoma – aggressive, high-grade, strongly linked to PCNSL
• Choroidal lymphoma – usually indolent, low-grade B-cell lymphoma
• Secondary intraocular involvement from systemic lymphoma

These disorders differ substantially in:

• Clinical appearance
• Biology
• CNS association
• Prognosis
• Treatment

Who Is Most Often Affected

PVRL occurs predominantly in:

• Older adults
• Typically sixth to seventh decade or later

It can occur in:

• Immunocompetent individuals
• Immunocompromised patients

Disease in children is exceptionally rare.

Relationship to the Central Nervous System

The most important systemic association is:

Primary CNS lymphoma.

PVRL is generally regarded as part of the PCNS lymphoma spectrum.

Patients may present with:

• Eye disease alone
• CNS disease alone
• Both simultaneously

A substantial proportion of patients who initially have apparently isolated ocular disease later develop:

CNS lymphoma.

This is why long-term neurologic surveillance is essential.

Bilateral Disease Is Common

PVRL is frequently:

Bilateral

but involvement may be:

• Asymmetric
• Sequential

One eye can therefore appear minimally involved while the fellow eye contains obvious disease.

What Causes It

The precise cause is not fully understood.

Most tumors arise from malignant B lymphocytes with characteristic molecular abnormalities.

Important modern molecular findings include:

• MYD88 L265P mutation
• CD79B pathway abnormalities
• B-cell receptor/NF-κB pathway activation
• Immunoglobulin gene clonality

These findings are diagnostically useful.

Important Modern Correction About Infection

Older literature proposed that:

• Epstein-Barr virus
• Herpesviruses
• Toxoplasma gondii

might directly cause PVRL.

In modern practice, these are:

Not considered established causes of typical PVRL in immunocompetent patients.

EBV is more relevant to certain lymphomas arising in severe immunosuppression.

How the Tumor Reaches Ocular Tissues

Malignant lymphocytes preferentially infiltrate:

• Vitreous
• Retina
• Sub-RPE space

rather than primarily involving the choroid.

This explains the classic combination of:

Vitreous cellular infiltration + creamy sub-RPE/retinal lesions.

What Patients Usually Notice

Typical symptoms include:

• Floaters
• Painless blurred vision
• Reduced contrast
• Hazy vision

Less commonly:

• Photopsias
• Visual field disturbances

Pain, severe redness, and photophobia are generally:

Less prominent than in ordinary inflammatory uveitis.

Why Diagnosis Is Often Delayed

PVRL frequently masquerades as:

Chronic intermediate or posterior uveitis.

Patients may initially be diagnosed with:

• Idiopathic vitritis
• Autoimmune uveitis
• Infectious uveitis

Transient improvement with corticosteroids may further delay the diagnosis.

The Classic Vitreous Appearance

The vitreous commonly contains:

• Sheets of cells
• Clumps of cells
• Fine particulate cellular haze

The appearance may resemble inflammatory vitritis but often has:

Dense cells with surprisingly little anterior-segment inflammation.

Characteristic Subretinal and Sub-RPE Lesions

A key finding is:

Creamy yellow-white infiltrates at or beneath the RPE.

They may appear as:

• Tiny dots
• Round lesions
• Plaques
• Confluent infiltrates

Early lesions can resemble:

• Drusen
• White-dot syndromes
• Inflammatory chorioretinal lesions

What Happens After Lesions Regress

Resolution of lymphoma infiltrates may leave:

• RPE mottling
• RPE atrophy
• Pigmentary disturbance
• Outer retinal loss

These residual changes can permanently reduce vision when the macula is involved.

Other Possible Ocular Findings

Less common findings include:

• Mild anterior chamber cells
• Keratic precipitates
• Retinal vascular sheathing
• Retinal hemorrhage
• Optic disc edema
• Subretinal fluid
• Epiretinal membrane

Frank hypopyon is unusual.

Optical Coherence Tomography

OCT has become extremely useful in suspected PVRL.

Possible findings include:

• Hyperreflective sub-RPE deposits
• Nodular RPE elevations
• Hyperreflective infiltrates within the retina
• Outer retinal disruption
• Ellipsoid zone loss
• RPE irregularity
• Subretinal hyperreflective material

Serial OCT can help monitor:

Response and recurrence.

A Characteristic OCT Clue

Vertical or column-like hyperreflective lesions extending through retinal layers have been described in PVRL.

Although not pathognomonic, such findings in an older patient with chronic unexplained vitritis should raise suspicion for:

Vitreoretinal lymphoma.

Fundus Autofluorescence

FAF may show a characteristic granular pattern of:

• Hyperautofluorescent spots
• Hypoautofluorescent spots

reflecting:

• Active RPE stress
• Infiltration
• RPE atrophy

A mottled “leopard-spot” pattern can occur.

Fluorescein Angiography

FA may demonstrate:

• RPE window defects
• Staining
• Blockage from infiltrates
• Vascular leakage
• Patchy hypofluorescent and hyperfluorescent lesions

It is supportive rather than diagnostic.

Indocyanine Green Angiography

ICGA may show:

• Hypofluorescent spots
• Areas of choroidal perfusion abnormality

but is generally less central to diagnosis than:

• OCT
• FAF
• Tissue/fluid analysis

Ultrasound Findings

B-scan may show:

• Vitreous opacities
• Mild focal retinal/choroidal thickening

It is mainly useful when:

Media opacity prevents fundus visualization.

Why MRI of the Brain Is Essential

Every patient with suspected or confirmed PVRL should undergo:

Contrast-enhanced MRI of the brain

to evaluate for:

• PCNS lymphoma
• Leptomeningeal disease
• Other CNS lesions

MRI is preferred over CT for detecting CNS lymphoma.

Typical CNS Lymphoma Findings

PCNS lymphoma often produces:

• Homogeneously enhancing lesions
• Deep periventricular lesions
• Corpus callosum involvement
• Basal ganglia or deep white matter lesions

However, the CNS MRI can be normal when ocular disease first appears.

Neurologic Symptoms to Ask About

Patients should be questioned about:

• Cognitive change
• Personality change
• Headache
• Seizures
• Weakness
• Gait disturbance
• Cranial nerve symptoms

New neurologic symptoms in a patient with PVRL require:

Prompt CNS reassessment.

Role of Lumbar Puncture

CSF analysis may include:

• Cytology
• Flow cytometry
• Molecular studies

It is particularly useful when:

• MRI shows suspicious CNS lesions
• Leptomeningeal involvement is suspected
• Neurologic symptoms are present

An important correction is that:

Lumbar puncture is not invariably required in every patient before the diagnosis of PVRL can be established.

It is performed according to the neurologic and oncologic assessment.

Why the Diagnosis Can Be Difficult

Lymphoma cells are:

Fragile

and may rapidly degenerate after specimen collection.

Diagnostic difficulty is increased by:

• Small samples
• Low tumor-cell concentration
• Abundant reactive inflammatory cells
• Previous corticosteroid treatment

Multiple tests and sometimes repeat biopsies are required.

Vitreous Biopsy

When PVRL is strongly suspected, a:

Diagnostic pars plana vitrectomy

is often the preferred method for obtaining adequate vitreous material.

The specimen should be handled rapidly and coordinated with:

• Cytopathology
• Hematopathology
• Molecular laboratory

before surgery.

Why Laboratory Coordination Matters

The surgeon should communicate with the laboratory in advance because vitreous must often be divided for:

• Cytology
• Flow cytometry
• Cytokine analysis
• Molecular testing

Improper handling can markedly decrease diagnostic yield.

Cytology

The traditional diagnostic cornerstone is identification of malignant lymphoid cells.

Typical cells are:

• Large
• Pleomorphic
• High nuclear-to-cytoplasmic ratio
• Prominent nucleoli
• Irregular nuclei

Most PVRL represents:

Large B-cell lymphoma.

Immunophenotyping

Typical B-cell markers include:

• CD20
• CD19
• CD79a
• PAX5

Demonstration of a clonal B-cell population supports lymphoma.

Flow cytometry may also evaluate:

Kappa/lambda light-chain restriction.

MYD88 Mutation Testing

One of the most useful modern diagnostic advances is detection of:

MYD88 L265P

in ocular fluid.

The mutation is present in a large proportion of PVRL and PCNS lymphoma cases.

Testing may be performed on:

• Vitreous
• Aqueous humor

Detection strongly supports the diagnosis in the appropriate clinical setting.

Why Aqueous Humor Is Increasingly Useful

Modern molecular techniques can detect:

• MYD88 mutation
• Tumor-derived DNA
• Cytokines

from small aqueous samples.

This provides a:

Less invasive adjunct to vitreous biopsy

although a negative aqueous test does not exclude PVRL.

Immunoglobulin Gene Rearrangement

PCR demonstrating clonal:

Immunoglobulin heavy-chain gene rearrangement

supports B-cell lymphoma.

However, false-negative and occasional false-positive results can occur.

It should be interpreted alongside:

• Cytology
• Clinical findings
• Other molecular testing

IL-10 and IL-6

PVRL cells frequently produce large amounts of:

Interleukin-10 (IL-10).

Inflammatory uveitis tends to produce more:

Interleukin-6 (IL-6).

An:

IL-10:IL-6 ratio >1

supports lymphoma but is:

Not sufficiently specific to establish the diagnosis by itself.

Absolute IL-10 concentration may also be informative.

Modern Cell-Free DNA Testing

Next-generation sequencing and analysis of:

cell-free tumor DNA

in ocular fluid are emerging as highly useful tools.

These can detect combinations of:

• MYD88
• CD79B
• Other lymphoma-associated mutations

and may improve diagnostic sensitivity when cytology is nondiagnostic.

Availability varies by center.

Why Steroids Can Interfere With Diagnosis

Corticosteroids can cause:

Rapid apoptosis of lymphoma cells.

This may temporarily improve:

• Vitritis
• Vision
• Retinal infiltrates

while reducing biopsy yield.

When clinically safe:

Avoid or minimize corticosteroids before diagnostic sampling.

What to Do If the First Biopsy Is Negative

A negative vitreous biopsy does:

Not exclude PVRL.

If suspicion remains high:

• Repeat vitreous biopsy
• Test the fellow eye if involved
• Perform aqueous molecular testing
• Consider retinal/sub-RPE biopsy in exceptional cases
• Reassess CNS imaging

may be necessary.

Why Retinal Biopsy Is Rarely First-Line

Retinal or chorioretinal biopsy can provide diagnostic tissue but carries risks including:

• Retinal detachment
• Hemorrhage
• Permanent scotoma

It is generally reserved for:

Persistently unexplained cases despite less invasive testing.

The Classic Masquerade Syndrome

PVRL is one of the most important causes of:

Masquerade uveitis

especially in an older adult with:

• Chronic vitritis
• Poor or transient steroid response
• Recurrent inflammation
• Sub-RPE infiltrates

Persistent “idiopathic uveitis” in this setting should trigger reconsideration of the diagnosis.

Important Differential Diagnoses

These include:

• Syphilitic posterior uveitis
• Tuberculosis
• Toxoplasmosis
• Viral retinitis
• Sarcoidosis
• Birdshot chorioretinopathy
• Multifocal choroiditis
• Other white-dot syndromes
• Endogenous endophthalmitis
• Choroidal lymphoma
• Choroidal metastasis

Distinguishing PVRL From Choroidal Lymphoma

These are biologically different diseases.

Vitreoretinal Lymphoma

• High-grade DLBCL
• Dense vitreous cells common
• Retinal/sub-RPE infiltration
• Strong association with PCNS lymphoma

Choroidal Lymphoma

• Usually low-grade B-cell lymphoma
• Diffuse or multifocal yellow choroidal thickening
• Little vitritis
• May produce extrascleral “salmon-patch” extension
• More closely related to systemic marginal-zone lymphoma than PCNS lymphoma

Distinguishing It From Choroidal Metastasis

Choroidal metastases typically appear as:

• Yellow choroidal masses
• Often with subretinal fluid

They generally lack the characteristic combination of:

Dense vitreous cellular infiltration and sub-RPE lymphoma deposits.

Systemic cancer history can provide an additional clue.

Establishing the Extent of Disease

Once PVRL is diagnosed, evaluation should determine whether disease is:

• Eye only
• Eye + CNS
• Rarely related to systemic lymphoma

This generally involves:

• Neuro-oncology/hematology assessment
• Brain MRI
• CSF evaluation when appropriate
• Systemic staging when clinically indicated

Treatment Requires Multidisciplinary Care

Management should involve:

• Ocular oncology or uveitis/retina specialist
• Hematology-oncology
• Neuro-oncology
• Radiation oncology when appropriate

The ocular disease cannot be managed in isolation because CNS relapse is the major determinant of survival.

Treatment When CNS Disease Is Present

When PVRL accompanies PCNS lymphoma, treatment generally includes:

Systemic CNS-penetrating chemotherapy

centered around:

High-dose methotrexate (HD-MTX).

Additional agents may include:

• Rituximab
• Cytarabine
• Thiotepa
• Other CNS-directed chemotherapy

Regimen selection depends on:

• Age
• Performance status
• Renal function
• Treatment center

Modern PCNS Lymphoma Therapy

Contemporary induction regimens frequently combine:

High-dose methotrexate with other CNS-penetrating agents and rituximab.

For suitable patients, consolidation may include:

High-dose chemotherapy followed by autologous stem-cell transplantation.

This has reduced reliance on routine whole-brain radiotherapy in many patients.

Why Whole-Brain Radiation Is Used More Selectively

Whole-brain radiotherapy can control lymphoma but may cause:

Delayed neurocognitive toxicity, especially in older adults.

Therefore modern management often favors:

• Chemotherapy-based induction
• Stem-cell-based consolidation in eligible patients

with radiation reserved for selected situations.

Treatment of Isolated Ocular Disease

Options include:

• Intravitreal methotrexate
• Intravitreal rituximab
• Ocular radiotherapy
• Systemic CNS-directed treatment in selected patients
• Combination approaches

There is no single universally accepted regimen for every patient with isolated PVRL.

Intravitreal Methotrexate

Intravitreal methotrexate is one of the most established local therapies.

A commonly used dose is:

400 µg/0.1 mL

Treatment usually involves:

• Induction injections
• Consolidation
• Maintenance

although schedules vary substantially.

Methotrexate Ocular Toxicity

Repeated injections can cause:

• Corneal epitheliopathy
• Punctate keratopathy
• Epithelial defects
• Cataract
• Macular toxicity rarely

Corneal toxicity is one of the major dose-limiting complications.

Reducing Methotrexate Keratopathy

Strategies may include:

• Reducing injection frequency
• Temporary treatment interruption
• Intensive lubrication
• Folinic acid approaches in selected protocols

while maintaining adequate lymphoma control.

Intravitreal Rituximab

Rituximab, an anti-CD20 monoclonal antibody, can be given intravitreally.

A commonly used dose is:

1 mg/0.1 mL.

It may be used:

• Alone
• With methotrexate

and is particularly useful when methotrexate causes significant corneal toxicity.

Ocular Radiotherapy

External-beam radiotherapy can provide excellent local control.

Typical contemporary doses depend on treatment strategy but are usually considerably lower than historic tumoricidal doses used for many other malignancies.

Potential adverse effects include:

• Cataract
• Dry eye
• Radiation retinopathy
• Optic neuropathy
• Keratopathy

Risk depends on dose and field.

Bilateral Ocular Disease

When both eyes are involved, treatment options include:

• Bilateral local therapy
• Systemic CNS-directed therapy
• Combination treatment

Treatment should account for:

• Existing CNS disease
• Likelihood of CNS progression
• Patient age
• Ocular disease burden

Does Systemic Therapy Prevent CNS Lymphoma?

This remains an area of ongoing investigation.

Because ocular-only PVRL carries substantial risk of later CNS disease, some centers use:

Systemic CNS-directed therapy even when MRI is initially negative.

However, the optimal strategy remains debated and individualized.

Role of Vitrectomy Beyond Diagnosis

Vitrectomy may also:

• Clear visually significant vitreous haze
• Improve visual function
• Reduce cellular burden

but:

Vitrectomy alone is not curative.

Residual lymphoma cells remain in the retina and sub-RPE compartment.

Monitoring Treatment Response

Follow-up should include:

• Visual acuity
• Slit-lamp examination
• Vitreous cellular assessment
• Dilated retinal examination
• OCT
• FAF
• Fundus photography

Molecular or cytokine testing may occasionally assist in monitoring selected patients.

What Ocular Recurrence Can Look Like

Recurrence may present with:

• New floaters
• Increasing vitreous cells
• New sub-RPE deposits
• Recurrent outer retinal infiltration
• New RPE abnormalities

Because recurrence can be subtle, imaging should be compared carefully with:

Baseline studies.

CNS Surveillance

Patients with apparently isolated PVRL require:

Long-term neurologic surveillance.

This usually includes:

• Clinical neurologic review
• Serial brain MRI

The exact frequency is individualized according to:

• Initial disease pattern
• Treatment
• Oncology protocol

Why Long-Term Follow-Up Is Essential

PVRL can recur:

• In either eye
• In the CNS
• Years after initial therapy

Therefore apparent ocular remission does not mean the patient is:

Cured of the overall lymphoma risk.

Expected Visual Outcome

Vision depends on:

• Macular involvement
• Optic nerve involvement
• Degree of RPE/outer retinal destruction
• Treatment toxicity
• Recurrence

Vitritis alone may clear with good visual recovery.

Extensive macular sub-RPE infiltration may leave:

Permanent RPE and photoreceptor atrophy.

Systemic Prognosis

Prognosis is determined primarily by:

CNS involvement and response to lymphoma therapy.

Older literature often quoted survival of only 2–3 years.

This is no longer universally applicable because modern:

• High-dose methotrexate-based regimens
• Rituximab
• Intensive consolidation
• Autologous stem-cell transplantation

have improved outcomes in appropriately selected patients.

High-Yield Takeaways

• Primary vitreoretinal lymphoma is an aggressive diffuse large B-cell lymphoma of the vitreous, retina, and sub-RPE space and belongs to the primary CNS lymphoma spectrum.
• The older term “primary intraocular lymphoma” is less precise because choroidal lymphoma is a distinct intraocular lymphoma.
• PVRL typically affects older adults and is frequently bilateral but asymmetric.
• The classic presentation is painless blurred vision and floaters with chronic vitreous cells plus creamy yellow-white sub-RPE or retinal infiltrates.
• PVRL is a classic masquerade syndrome and should be considered in an older patient with chronic unexplained posterior uveitis.
• Temporary improvement with corticosteroids does not exclude lymphoma and can delay diagnosis.
• Avoid corticosteroids before biopsy when clinically feasible, because lymphoma cells are highly steroid-sensitive and diagnostic yield can fall substantially.
• OCT may show sub-RPE hyperreflective deposits, retinal infiltrates, outer retinal disruption, and RPE nodularity.
• Brain MRI with contrast is essential because of the strong association with PCNS lymphoma.
• CSF testing is useful when clinically indicated, but lumbar puncture is not an absolute prerequisite in every ocular presentation.
• Diagnostic vitrectomy requires careful advance coordination because lymphoma cells are fragile and rapidly degenerate.
• Cytology remains important but has limited sensitivity; diagnosis is increasingly strengthened by flow cytometry, IL-10 analysis, immunoglobulin clonality, and molecular testing.
• MYD88 L265P testing of vitreous or aqueous humor is a major modern diagnostic tool.
• Aqueous humor molecular testing and cell-free DNA analysis can provide useful less-invasive diagnostic evidence, although negative tests do not exclude PVRL.
• An IL-10:IL-6 ratio >1 supports lymphoma but cannot independently establish the diagnosis.
• Most PVRL is CD20-positive DLBCL.
• PVRL must be distinguished from choroidal lymphoma, which is usually low-grade, has little vitritis, and is not strongly associated with PCNS lymphoma.
• When CNS lymphoma is present, treatment centers on high-dose methotrexate-based systemic therapy, usually with modern multidrug regimens and often rituximab.
• Autologous stem-cell transplantation is now an important consolidation strategy for selected fit patients with PCNS lymphoma.
• Whole-brain radiotherapy is used more selectively because of delayed neurotoxicity, particularly in older adults.
• Local ocular treatment includes intravitreal methotrexate, intravitreal rituximab, and/or ocular radiotherapy.
• Repeated intravitreal methotrexate frequently causes corneal epitheliopathy, whereas rituximab can be useful as an alternative or adjunct.
• Vitrectomy can improve vitreous haze but is diagnostic and debulking, not curative.
• Patients with apparently isolated ocular disease remain at substantial risk of later CNS lymphoma and require long-term neurologic and MRI surveillance.
• Ocular prognosis depends mainly on macular/RPE damage, while overall survival depends predominantly on CNS disease and response to modern lymphoma therapy.

Why “Primary Intraocular Lymphoma” Is Less Precise The older term: Primary intraocular lymphoma is potentially confusing because several distinct lymphomas can occur inside the eye. These include:  Primary vitreoretinal lymphoma – aggressive, high-grade, strongly linked to PCNSL Choroidal lymphoma – usually indolent, low-grade B-cell lymphoma Secondary intraocular involvement from systemic lymphoma  These disorders differ substantially in:  Clinical appearance Biology CNS association Prognosis Treatment

Who Is Most Often Affected PVRL occurs predominantly in:  Older adults Typically sixth to seventh decade or later  It can occur in:  Immunocompetent individuals Immunocompromised patients  Disease in children is exceptionally rare.

Relationship to the Central Nervous System The most important systemic association is: Primary CNS lymphoma. PVRL is generally regarded as part of the PCNS lymphoma spectrum. Patients may present with:  Eye disease alone CNS disease alone Both simultaneously  A substantial proportion of patients who initially have apparently isolated ocular disease later develop: CNS lymphoma. This is why long-term neurologic surveillance is essential.

Bilateral Disease Is Common PVRL is frequently: Bilateral but involvement may be:  Asymmetric Sequential  One eye can therefore appear minimally involved while the fellow eye contains obvious disease.

What Causes It The precise cause is not fully understood. Most tumors arise from malignant B lymphocytes with characteristic molecular abnormalities. Important modern molecular findings include:  MYD88 L265P mutation CD79B pathway abnormalities B-cell receptor/NF-κB pathway activation Immunoglobulin gene clonality  These findings are diagnostically useful.

Important Modern Correction About Infection Older literature proposed that:  Epstein-Barr virus Herpesviruses Toxoplasma gondii  might directly cause PVRL. In modern practice, these are: Not considered established causes of typical PVRL in immunocompetent patients. EBV is more relevant to certain lymphomas arising in severe immunosuppression.

How the Tumor Reaches Ocular Tissues Malignant lymphocytes preferentially infiltrate:  Vitreous Retina Sub-RPE space  rather than primarily involving the choroid. This explains the classic combination of: Vitreous cellular infiltration + creamy sub-RPE/retinal lesions.

What Patients Usually Notice Typical symptoms include:  Floaters Painless blurred vision Reduced contrast Hazy vision  Less commonly:  Photopsias Visual field disturbances  Pain, severe redness, and photophobia are generally: Less prominent than in ordinary inflammatory uveitis.

Why Diagnosis Is Often Delayed PVRL frequently masquerades as: Chronic intermediate or posterior uveitis. Patients may initially be diagnosed with:  Idiopathic vitritis Autoimmune uveitis Infectious uveitis  Transient improvement with corticosteroids may further delay the diagnosis.

The Classic Vitreous Appearance The vitreous commonly contains:  Sheets of cells Clumps of cells Fine particulate cellular haze  The appearance may resemble inflammatory vitritis but often has: Dense cells with surprisingly little anterior-segment inflammation.

Characteristic Subretinal and Sub-RPE Lesions A key finding is: Creamy yellow-white infiltrates at or beneath the RPE. They may appear as:  Tiny dots Round lesions Plaques Confluent infiltrates  Early lesions can resemble:  Drusen White-dot syndromes Inflammatory chorioretinal lesions

What Happens After Lesions Regress Resolution of lymphoma infiltrates may leave:  RPE mottling RPE atrophy Pigmentary disturbance Outer retinal loss  These residual changes can permanently reduce vision when the macula is involved.

Other Possible Ocular Findings Less common findings include:  Mild anterior chamber cells Keratic precipitates Retinal vascular sheathing Retinal hemorrhage Optic disc edema Subretinal fluid Epiretinal membrane  Frank hypopyon is unusual.

Optical Coherence Tomography OCT has become extremely useful in suspected PVRL. Possible findings include:  Hyperreflective sub-RPE deposits Nodular RPE elevations Hyperreflective infiltrates within the retina Outer retinal disruption Ellipsoid zone loss RPE irregularity Subretinal hyperreflective material  Serial OCT can help monitor: Response and recurrence.

A Characteristic OCT Clue Vertical or column-like hyperreflective lesions extending through retinal layers have been described in PVRL. Although not pathognomonic, such findings in an older patient with chronic unexplained vitritis should raise suspicion for: Vitreoretinal lymphoma.

Fundus Autofluorescence FAF may show a characteristic granular pattern of:  Hyperautofluorescent spots Hypoautofluorescent spots  reflecting:  Active RPE stress Infiltration RPE atrophy  A mottled “leopard-spot” pattern can occur.

Fluorescein Angiography FA may demonstrate:  RPE window defects Staining Blockage from infiltrates Vascular leakage Patchy hypofluorescent and hyperfluorescent lesions  It is supportive rather than diagnostic.

Indocyanine Green Angiography ICGA may show:  Hypofluorescent spots Areas of choroidal perfusion abnormality  but is generally less central to diagnosis than:  OCT FAF Tissue/fluid analysis

Ultrasound Findings B-scan may show:  Vitreous opacities Mild focal retinal/choroidal thickening  It is mainly useful when: Media opacity prevents fundus visualization.

Why MRI of the Brain Is Essential Every patient with suspected or confirmed PVRL should undergo: Contrast-enhanced MRI of the brain to evaluate for:  PCNS lymphoma Leptomeningeal disease Other CNS lesions  MRI is preferred over CT for detecting CNS lymphoma.

Typical CNS Lymphoma Findings PCNS lymphoma often produces:  Homogeneously enhancing lesions Deep periventricular lesions Corpus callosum involvement Basal ganglia or deep white matter lesions  However, the CNS MRI can be normal when ocular disease first appears.

Neurologic Symptoms to Ask About Patients should be questioned about:  Cognitive change Personality change Headache Seizures Weakness Gait disturbance Cranial nerve symptoms  New neurologic symptoms in a patient with PVRL require: Prompt CNS reassessment.

Role of Lumbar Puncture CSF analysis may include:  Cytology Flow cytometry Molecular studies  It is particularly useful when:  MRI shows suspicious CNS lesions Leptomeningeal involvement is suspected Neurologic symptoms are present  An important correction is that: Lumbar puncture is not invariably required in every patient before the diagnosis of PVRL can be established. It is performed according to the neurologic and oncologic assessment.

Why the Diagnosis Can Be Difficult Lymphoma cells are: Fragile and may rapidly degenerate after specimen collection. Diagnostic difficulty is increased by:  Small samples Low tumor-cell concentration Abundant reactive inflammatory cells Previous corticosteroid treatment  Multiple tests and sometimes repeat biopsies are required.

Vitreous Biopsy When PVRL is strongly suspected, a: Diagnostic pars plana vitrectomy is often the preferred method for obtaining adequate vitreous material. The specimen should be handled rapidly and coordinated with:  Cytopathology Hematopathology Molecular laboratory  before surgery.

Why Laboratory Coordination Matters The surgeon should communicate with the laboratory in advance because vitreous must often be divided for:  Cytology Flow cytometry Cytokine analysis Molecular testing  Improper handling can markedly decrease diagnostic yield.

Cytology The traditional diagnostic cornerstone is identification of malignant lymphoid cells. Typical cells are:  Large Pleomorphic High nuclear-to-cytoplasmic ratio Prominent nucleoli Irregular nuclei  Most PVRL represents: Large B-cell lymphoma.

Immunophenotyping Typical B-cell markers include:  CD20 CD19 CD79a PAX5  Demonstration of a clonal B-cell population supports lymphoma. Flow cytometry may also evaluate: Kappa/lambda light-chain restriction.

MYD88 Mutation Testing One of the most useful modern diagnostic advances is detection of: MYD88 L265P in ocular fluid. The mutation is present in a large proportion of PVRL and PCNS lymphoma cases. Testing may be performed on:  Vitreous Aqueous humor  Detection strongly supports the diagnosis in the appropriate clinical setting.

Why Aqueous Humor Is Increasingly Useful Modern molecular techniques can detect:  MYD88 mutation Tumor-derived DNA Cytokines  from small aqueous samples. This provides a: Less invasive adjunct to vitreous biopsy although a negative aqueous test does not exclude PVRL.

Immunoglobulin Gene Rearrangement PCR demonstrating clonal: Immunoglobulin heavy-chain gene rearrangement supports B-cell lymphoma. However, false-negative and occasional false-positive results can occur. It should be interpreted alongside:  Cytology Clinical findings Other molecular testing

IL-10 and IL-6 PVRL cells frequently produce large amounts of: Interleukin-10 (IL-10). Inflammatory uveitis tends to produce more: Interleukin-6 (IL-6). An: IL-10:IL-6 ratio >1 supports lymphoma but is: Not sufficiently specific to establish the diagnosis by itself. Absolute IL-10 concentration may also be informative.

Modern Cell-Free DNA Testing Next-generation sequencing and analysis of: cell-free tumor DNA in ocular fluid are emerging as highly useful tools. These can detect combinations of:  MYD88 CD79B Other lymphoma-associated mutations  and may improve diagnostic sensitivity when cytology is nondiagnostic. Availability varies by center.

Why Steroids Can Interfere With Diagnosis Corticosteroids can cause: Rapid apoptosis of lymphoma cells. This may temporarily improve:  Vitritis Vision Retinal infiltrates  while reducing biopsy yield. When clinically safe: Avoid or minimize corticosteroids before diagnostic sampling.

What to Do If the First Biopsy Is Negative A negative vitreous biopsy does: Not exclude PVRL. If suspicion remains high:  Repeat vitreous biopsy Test the fellow eye if involved Perform aqueous molecular testing Consider retinal/sub-RPE biopsy in exceptional cases Reassess CNS imaging  may be necessary.

Why Retinal Biopsy Is Rarely First-Line Retinal or chorioretinal biopsy can provide diagnostic tissue but carries risks including:  Retinal detachment Hemorrhage Permanent scotoma  It is generally reserved for: Persistently unexplained cases despite less invasive testing.

The Classic Masquerade Syndrome PVRL is one of the most important causes of: Masquerade uveitis especially in an older adult with:  Chronic vitritis Poor or transient steroid response Recurrent inflammation Sub-RPE infiltrates  Persistent “idiopathic uveitis” in this setting should trigger reconsideration of the diagnosis.

Important Differential Diagnoses These include:  Syphilitic posterior uveitis Tuberculosis Toxoplasmosis Viral retinitis Sarcoidosis Birdshot chorioretinopathy Multifocal choroiditis Other white-dot syndromes Endogenous endophthalmitis Choroidal lymphoma Choroidal metastasis

Distinguishing PVRL From Choroidal Lymphoma These are biologically different diseases. Vitreoretinal Lymphoma  High-grade DLBCL Dense vitreous cells common Retinal/sub-RPE infiltration Strong association with PCNS lymphoma  Choroidal Lymphoma  Usually low-grade B-cell lymphoma Diffuse or multifocal yellow choroidal thickening Little vitritis May produce extrascleral “salmon-patch” extension More closely related to systemic marginal-zone lymphoma than PCNS lymphoma

Distinguishing It From Choroidal Metastasis Choroidal metastases typically appear as:  Yellow choroidal masses Often with subretinal fluid  They generally lack the characteristic combination of: Dense vitreous cellular infiltration and sub-RPE lymphoma deposits. Systemic cancer history can provide an additional clue.

Establishing the Extent of Disease Once PVRL is diagnosed, evaluation should determine whether disease is:  Eye only Eye + CNS Rarely related to systemic lymphoma  This generally involves:  Neuro-oncology/hematology assessment Brain MRI CSF evaluation when appropriate Systemic staging when clinically indicated

Treatment Requires Multidisciplinary Care Management should involve:  Ocular oncology or uveitis/retina specialist Hematology-oncology Neuro-oncology Radiation oncology when appropriate  The ocular disease cannot be managed in isolation because CNS relapse is the major determinant of survival.

Treatment When CNS Disease Is Present When PVRL accompanies PCNS lymphoma, treatment generally includes: Systemic CNS-penetrating chemotherapy centered around: High-dose methotrexate (HD-MTX). Additional agents may include:  Rituximab Cytarabine Thiotepa Other CNS-directed chemotherapy  Regimen selection depends on:  Age Performance status Renal function Treatment center

Modern PCNS Lymphoma Therapy Contemporary induction regimens frequently combine: High-dose methotrexate with other CNS-penetrating agents and rituximab. For suitable patients, consolidation may include: High-dose chemotherapy followed by autologous stem-cell transplantation. This has reduced reliance on routine whole-brain radiotherapy in many patients.

Why Whole-Brain Radiation Is Used More Selectively Whole-brain radiotherapy can control lymphoma but may cause: Delayed neurocognitive toxicity, especially in older adults. Therefore modern management often favors:  Chemotherapy-based induction Stem-cell-based consolidation in eligible patients  with radiation reserved for selected situations.

Treatment of Isolated Ocular Disease Options include:  Intravitreal methotrexate Intravitreal rituximab Ocular radiotherapy Systemic CNS-directed treatment in selected patients Combination approaches  There is no single universally accepted regimen for every patient with isolated PVRL.

Intravitreal Methotrexate Intravitreal methotrexate is one of the most established local therapies. A commonly used dose is: 400 µg/0.1 mL Treatment usually involves:  Induction injections Consolidation Maintenance  although schedules vary substantially.

Methotrexate Ocular Toxicity Repeated injections can cause:  Corneal epitheliopathy Punctate keratopathy Epithelial defects Cataract Macular toxicity rarely  Corneal toxicity is one of the major dose-limiting complications.

Reducing Methotrexate Keratopathy Strategies may include:  Reducing injection frequency Temporary treatment interruption Intensive lubrication Folinic acid approaches in selected protocols  while maintaining adequate lymphoma control.

Intravitreal Rituximab Rituximab, an anti-CD20 monoclonal antibody, can be given intravitreally. A commonly used dose is: 1 mg/0.1 mL. It may be used:  Alone With methotrexate  and is particularly useful when methotrexate causes significant corneal toxicity.

Ocular Radiotherapy External-beam radiotherapy can provide excellent local control. Typical contemporary doses depend on treatment strategy but are usually considerably lower than historic tumoricidal doses used for many other malignancies. Potential adverse effects include:  Cataract Dry eye Radiation retinopathy Optic neuropathy Keratopathy  Risk depends on dose and field.

Bilateral Ocular Disease When both eyes are involved, treatment options include:  Bilateral local therapy Systemic CNS-directed therapy Combination treatment  Treatment should account for:  Existing CNS disease Likelihood of CNS progression Patient age Ocular disease burden

Does Systemic Therapy Prevent CNS Lymphoma? This remains an area of ongoing investigation. Because ocular-only PVRL carries substantial risk of later CNS disease, some centers use: Systemic CNS-directed therapy even when MRI is initially negative. However, the optimal strategy remains debated and individualized.

Role of Vitrectomy Beyond Diagnosis Vitrectomy may also:  Clear visually significant vitreous haze Improve visual function Reduce cellular burden  but: Vitrectomy alone is not curative. Residual lymphoma cells remain in the retina and sub-RPE compartment.

Monitoring Treatment Response Follow-up should include:  Visual acuity Slit-lamp examination Vitreous cellular assessment Dilated retinal examination OCT FAF Fundus photography  Molecular or cytokine testing may occasionally assist in monitoring selected patients.

What Ocular Recurrence Can Look Like Recurrence may present with:  New floaters Increasing vitreous cells New sub-RPE deposits Recurrent outer retinal infiltration New RPE abnormalities  Because recurrence can be subtle, imaging should be compared carefully with: Baseline studies.

CNS Surveillance Patients with apparently isolated PVRL require: Long-term neurologic surveillance. This usually includes:  Clinical neurologic review Serial brain MRI  The exact frequency is individualized according to:  Initial disease pattern Treatment Oncology protocol

Why Long-Term Follow-Up Is Essential PVRL can recur:  In either eye In the CNS Years after initial therapy  Therefore apparent ocular remission does not mean the patient is: Cured of the overall lymphoma risk.

Expected Visual Outcome Vision depends on:  Macular involvement Optic nerve involvement Degree of RPE/outer retinal destruction Treatment toxicity Recurrence  Vitritis alone may clear with good visual recovery. Extensive macular sub-RPE infiltration may leave: Permanent RPE and photoreceptor atrophy.

Systemic Prognosis Prognosis is determined primarily by: CNS involvement and response to lymphoma therapy. Older literature often quoted survival of only 2–3 years. This is no longer universally applicable because modern:  High-dose methotrexate-based regimens Rituximab Intensive consolidation Autologous stem-cell transplantation  have improved outcomes in appropriately selected patients.

High-Yield Takeaways  Primary vitreoretinal lymphoma is an aggressive diffuse large B-cell lymphoma of the vitreous, retina, and sub-RPE space and belongs to the primary CNS lymphoma spectrum. The older term “primary intraocular lymphoma” is less precise because choroidal lymphoma is a distinct intraocular lymphoma. PVRL typically affects older adults and is frequently bilateral but asymmetric. The classic presentation is painless blurred vision and floaters with chronic vitreous cells plus creamy yellow-white sub-RPE or retinal infiltrates. PVRL is a classic masquerade syndrome and should be considered in an older patient with chronic unexplained posterior uveitis. Temporary improvement with corticosteroids does not exclude lymphoma and can delay diagnosis. Avoid corticosteroids before biopsy when clinically feasible, because lymphoma cells are highly steroid-sensitive and diagnostic yield can fall substantially. OCT may show sub-RPE hyperreflective deposits, retinal infiltrates, outer retinal disruption, and RPE nodularity. Brain MRI with contrast is essential because of the strong association with PCNS lymphoma. CSF testing is useful when clinically indicated, but lumbar puncture is not an absolute prerequisite in every ocular presentation. Diagnostic vitrectomy requires careful advance coordination because lymphoma cells are fragile and rapidly degenerate. Cytology remains important but has limited sensitivity; diagnosis is increasingly strengthened by flow cytometry, IL-10 analysis, immunoglobulin clonality, and molecular testing. MYD88 L265P testing of vitreous or aqueous humor is a major modern diagnostic tool. Aqueous humor molecular testing and cell-free DNA analysis can provide useful less-invasive diagnostic evidence, although negative tests do not exclude PVRL. An IL-10:IL-6 ratio >1 supports lymphoma but cannot independently establish the diagnosis. Most PVRL is CD20-positive DLBCL. PVRL must be distinguished from choroidal lymphoma, which is usually low-grade, has little vitritis, and is not strongly associated with PCNS lymphoma. When CNS lymphoma is present, treatment centers on high-dose methotrexate-based systemic therapy, usually with modern multidrug regimens and often rituximab. Autologous stem-cell transplantation is now an important consolidation strategy for selected fit patients with PCNS lymphoma. Whole-brain radiotherapy is used more selectively because of delayed neurotoxicity, particularly in older adults. Local ocular treatment includes intravitreal methotrexate, intravitreal rituximab, and/or ocular radiotherapy. Repeated intravitreal methotrexate frequently causes corneal epitheliopathy, whereas rituximab can be useful as an alternative or adjunct. Vitrectomy can improve vitreous haze but is diagnostic and debulking, not curative. Patients with apparently isolated ocular disease remain at substantial risk of later CNS lymphoma and require long-term neurologic and MRI surveillance. Ocular prognosis depends mainly on macular/RPE damage, while overall survival depends predominantly on CNS disease and response to modern lymphoma therapy.

Ophthalmology – Vitamin A Deficiency/Xerophthalmia

What the Disorder Represents

Xerophthalmia is the spectrum of ocular disease caused by vitamin A deficiency (VAD).

It progresses from functional retinal dysfunction to destructive ocular-surface disease:

Night blindness → conjunctival xerosis → Bitot spots → corneal xerosis → corneal ulceration/keratomalacia → permanent corneal scarring or blindness

Vitamin A deficiency is also a systemic nutritional disorder associated with:

• Impaired immunity
• Increased susceptibility to infection
• Poor growth in children
• Increased childhood morbidity and mortality

Where the Disease Is Most Important

Clinical xerophthalmia is uncommon in well-nourished populations but remains an important public-health problem in areas with:

• Food insecurity
• Malnutrition
• Limited dietary diversity
• High childhood infection burden
• Poor access to healthcare

The greatest burden occurs particularly in parts of:

• Sub-Saharan Africa
• South and Southeast Asia

Young children are especially vulnerable.

Who Is at Greatest Risk

Important risk groups include:

• Preschool children
• Severe protein-energy malnutrition
• Food insecurity
• Restricted diets
• Chronic diarrhea
• Malabsorption
• Chronic liver or pancreatic disease
• Bariatric or gastrointestinal surgery
• Cystic fibrosis
• Cholestatic disorders
• Inflammatory bowel disease
• Severe eating disorders

Pregnancy and lactation increase vitamin A requirements, although high-dose supplementation requires particular caution.

Why Measles Matters

Vitamin A deficiency and measles have a particularly dangerous relationship.

Children with measles may develop:

• Rapid depletion of vitamin A stores
• Severe xerophthalmia
• Corneal ulceration
• Keratomalacia

Vitamin A supplementation is therefore routinely recommended for children with measles according to age-based public-health guidelines.

How Vitamin A Supports Vision

Vitamin A has two major ocular functions.

In the Retina

Vitamin A is required to generate:

11-cis-retinal

which combines with opsin to form visual pigments such as:

Rhodopsin

in rod photoreceptors.

Deficiency therefore first impairs:

Dark adaptation and night vision.

On the Ocular Surface

Vitamin A maintains normal differentiation of:

• Conjunctival epithelium
• Corneal epithelium
• Goblet cells

Deficiency causes:

Loss of goblet cells + squamous metaplasia + keratinization → severe ocular-surface dryness.

Why Protein and Zinc Status Matter

Vitamin A circulates bound to:

Retinol-binding protein (RBP).

Adequate protein and zinc are needed for normal:

• RBP synthesis
• Retinol transport
• Vitamin A metabolism

Severe malnutrition can therefore impair vitamin A delivery even when some hepatic stores remain.

Sources of Vitamin A

Vitamin A is obtained as:

Preformed Vitamin A

From animal foods such as:

• Liver
• Eggs
• Dairy products
• Fish

Provitamin A Carotenoids

From plant foods such as:

• Carrots
• Sweet potatoes
• Pumpkin
• Dark green leafy vegetables
• Orange/yellow fruits

Plant carotenoids require intestinal conversion to retinol and are generally:

Less bioavailable than preformed vitamin A.

The Earliest Ocular Symptom

The classic earliest symptom is:

Night blindness (nyctalopia).

Patients may report:

• Difficulty seeing after sunset
• Slow dark adaptation
• Trouble navigating dim rooms

Children may become reluctant to move around after dark.

Why Night Blindness Comes First

Rod photoreceptors depend heavily on rhodopsin regeneration.

Vitamin A depletion therefore affects:

Scotopic vision before central daylight acuity.

Night blindness can improve rapidly after vitamin A replacement.

WHO Xerophthalmia Classification

The classic WHO clinical grading system includes:

• XN – night blindness
• X1A – conjunctival xerosis
• X1B – Bitot spots
• X2 – corneal xerosis
• X3A – corneal ulceration/keratomalacia involving <1/3 of cornea
• X3B – corneal ulceration/keratomalacia involving ≥1/3 of cornea
• XS – corneal scar from xerophthalmia
• XF – xerophthalmic fundus

This remains useful for recognizing disease severity.

Conjunctival Xerosis

The conjunctiva loses its normal:

• Smoothness
• Luster
• Moist appearance

and becomes:

• Dry
• Dull
• Wrinkled
• Keratinized

Changes are often most apparent on the:

Temporal bulbar conjunctiva.

Bitot Spots

Bitot spots are characteristic superficial conjunctival lesions composed of keratinized epithelium and debris.

They typically appear as:

• White or gray
• Foamy
• Triangular or irregular plaques

most commonly on the:

Temporal bulbar conjunctiva near the limbus.

Why Bitot Spots Look Foamy

The characteristic frothy appearance results from:

• Keratinized epithelial debris
• Lipid
• Colonization by surface organisms

They strongly suggest xerophthalmia in the appropriate nutritional context.

Corneal Xerosis

More advanced deficiency causes the cornea to become:

• Dry
• Hazy
• Irregular
• Poorly wettable

The normal smooth epithelial surface is lost.

This stage can progress rapidly to:

Corneal ulceration and melting.

Keratomalacia

Keratomalacia is liquefactive corneal necrosis caused by severe vitamin A deficiency.

It may lead to:

• Stromal melting
• Descemetocele
• Perforation
• Endophthalmitis
• Loss of the eye

Keratomalacia is an:

Ophthalmic and systemic nutritional emergency.

Why Keratomalacia Can Progress So Rapidly

Severe VAD produces:

• Profound epithelial breakdown
• Loss of ocular-surface barrier function
• Stromal degradation
• Increased susceptibility to secondary infection

Corneal destruction may progress over:

Hours to days.

Xerophthalmic Fundus

Rarely, vitamin A deficiency causes a retinal appearance known as:

Xerophthalmic fundus

with multiple:

• Small
• Yellow-white
• Discrete retinal/RPE lesions

These changes are far less common than the anterior segment manifestations.

Typical Laterality

Nutritional vitamin A deficiency is a systemic disorder, so ocular findings are usually:

Bilateral

although severity may be asymmetric.

A highly unilateral presentation should prompt consideration of another diagnosis.

How the Diagnosis Is Made

Diagnosis is based on:

1. Compatible ocular findings
2. Nutritional or malabsorption risk
3. Systemic context
4. Serum retinol when useful

Treatment should not be delayed in severe clinical xerophthalmia while waiting for laboratory confirmation.

Serum Retinol – Important Modern Correction

Older reference ranges are sometimes reported incorrectly.

Vitamin A status is generally assessed using:

Serum retinol concentration.

A level below approximately:

0.70 µmol/L

supports vitamin A deficiency.

More severe deficiency is often considered around:

<0.35 µmol/L.

Why Serum Retinol Is Imperfect

Serum retinol can fall during:

• Acute infection
• Systemic inflammation
• Protein deficiency

because RBP behaves as a negative acute-phase reactant.

Therefore serum retinol must be interpreted alongside:

• Nutritional history
• CRP/inflammatory status
• Clinical findings

Other Laboratory Tests

Depending on the clinical context, evaluation may include:

• CBC
• Albumin
• Liver function
• Zinc
• Other fat-soluble vitamins
• Tests for malabsorption

RBP may sometimes serve as a surrogate marker but is not required routinely.

Conjunctival Impression Cytology

Impression cytology can demonstrate:

• Loss of goblet cells
• Squamous metaplasia
• Keratinization

It is primarily useful for:

• Research
• Population studies
• Selected diagnostic uncertainty

rather than routine management of obvious xerophthalmia.

Schirmer Testing Is Not the Main Diagnostic Test

Older descriptions emphasized Schirmer testing.

However, xerophthalmia is not simply ordinary aqueous-deficient dry eye.

The defining problem is:

Vitamin A–dependent epithelial failure and keratinization.

Schirmer testing may describe tear production but does not establish the diagnosis.

Tear Break-Up Time

TBUT may be abnormal because the ocular surface and mucin layer are disrupted.

Again, this is supportive rather than diagnostic.

Modern diagnosis centers on:

Clinical xerophthalmic signs and systemic vitamin A status.

Important Diagnostic Alternatives

Consider other causes of severe dry or keratinized ocular surface disease, including:

• Sjögren disease
• Stevens–Johnson syndrome
• Toxic epidermal necrolysis
• Ocular mucous membrane pemphigoid
• Chemical injury
• Severe exposure keratopathy
• Neurotrophic keratopathy
• Limbal stem-cell deficiency
• Severe medication toxicity

Distinguishing Xerophthalmia From Ordinary Dry Eye

Typical dry-eye disease may cause:

• Burning
• Fluctuating vision
• Punctate staining

but does not ordinarily produce the classic progression of:

Night blindness → Bitot spots → corneal xerosis → keratomalacia.

Systemic nutritional clues are crucial.

Immediate Treatment Principle

Once xerophthalmia from VAD is suspected:

Systemic vitamin A replacement should be given urgently.

Topical lubrication alone is inadequate.

The goal is to restore vitamin A rapidly before irreversible corneal destruction develops.

Standard WHO-Style Vitamin A Treatment

For children ≥12 months and adults, a commonly used regimen is:

200,000 IU vitamin A orally immediately, repeated the next day, and again after approximately 2 weeks.

Age-adjusted pediatric dosing is used for younger children:

• 6–11 months: 100,000 IU per dose
• <6 months: 50,000 IU per dose

Exact dosing should follow current local/WHO guidance.

Important Correction to Older Two-Dose Regimens

Older texts often listed only:

• Day 1
• Day 2

Modern treatment protocols typically include a:

Third dose approximately 2 weeks later

to replenish hepatic stores and reduce relapse.

When Oral Absorption Is Unreliable

If there is:

• Severe malabsorption
• Persistent vomiting
• Inability to take oral medication

parenteral vitamin A may be considered under specialist guidance.

The exact preparation and dosing depend on:

• Available formulation
• Age
• Systemic condition

Pregnancy Considerations

High-dose vitamin A supplementation requires special caution in pregnancy because excessive preformed vitamin A can be:

Teratogenic.

Pregnant patients with suspected deficiency require:

• Obstetric involvement
• Nutritional assessment
• Guideline-based replacement

Routine megadose therapy should not be improvised.

Ocular Surface Support

Adjunctive treatment may include:

• Preservative-free artificial tears
• Lubricating ointment
• Moisture protection

These help protect the epithelium while systemic deficiency is corrected.

Corneal Epithelial Defect or Ulceration

When epithelial breakdown is present:

• Intensive lubrication
• Close ophthalmic follow-up
• Topical antimicrobial prophylaxis or treatment when appropriate
• Cycloplegia for discomfort in selected cases

may be required.

Secondary microbial infection must be actively excluded.

Why Punctal Plugs Are Not Central Therapy

Older dry-eye approaches sometimes suggested punctal occlusion.

In xerophthalmia, however, the fundamental problem is:

Systemic epithelial vitamin A deficiency, not simply inadequate aqueous retention.

Punctal plugs do not correct the underlying disease and are rarely a priority during active severe xerophthalmia.

Topical Retinoic Acid – Modern Position

Topical retinoic acid has been investigated historically.

It is:

Not routine modern treatment

because:

• Systemic vitamin A replacement is the definitive therapy
• Topical formulations may irritate the surface
• Evidence for clinically meaningful additional benefit is limited

Keratomalacia Management

Keratomalacia requires:

Immediate systemic vitamin A replacement plus intensive corneal management.

Treatment may include:

• Broad-spectrum topical antibiotics if ulceration is present
• Intensive lubrication
• Protection from exposure
• Management of perforation
• Correction of severe malnutrition

These patients often require hospital-level multidisciplinary care.

Why Nutritional Rehabilitation Is Essential

Vitamin A deficiency often coexists with:

• Protein-energy malnutrition
• Zinc deficiency
• Other micronutrient deficiencies
• Infection
• Diarrheal disease

Giving vitamin A without correcting the underlying nutritional disorder can lead to:

Incomplete recovery or recurrence.

Treating the Cause of Malabsorption

In adults from well-nourished settings, severe VAD should trigger evaluation for:

• Bariatric surgery
• Pancreatic insufficiency
• Cholestasis
• Celiac disease
• Crohn disease
• Cystic fibrosis
• Chronic liver disease

Management must address the cause, not merely replace the vitamin.

Corneal Surgery

Surgery has little role during active keratomalacia because tissue may be:

• Necrotic
• Inflamed
• Poorly healing

Emergency tectonic surgery may occasionally be required for perforation.

Once:

• Nutrition is restored
• Surface disease is stable
• Inflammation has resolved

a visually significant corneal scar may potentially be treated with:

• Keratoplasty

but prognosis depends on ocular-surface health.

Why Corneal Transplantation Can Be Difficult

Graft prognosis is poorer when there is:

• Persistent surface keratinization
• Severe dry eye
• Vascularization
• Active malnutrition
• Limbal stem-cell dysfunction

Systemic and surface stabilization should precede elective transplantation.

Visual Recovery

Early disease often improves dramatically after treatment.

Night Blindness

May improve within:

Days

Conjunctival and Early Corneal Xerosis

Can improve over:

Days to weeks

Corneal Scarring

Once established, scar-related visual loss is:

Permanent unless surgically rehabilitated.

Prevention at Population Level

Public-health prevention includes:

• Dietary diversification
• Breastfeeding
• Food fortification
• Vitamin A supplementation programs in high-risk populations
• Measles vaccination
• Control of diarrheal disease
• Improved food security

These interventions reduce both ocular disease and childhood mortality.

Dietary Prevention

Useful vitamin A sources include:

Animal Sources

• Liver
• Eggs
• Dairy products
• Fish

Plant Sources Rich in Provitamin A

• Sweet potato
• Carrot
• Pumpkin
• Spinach
• Other dark-green leafy vegetables
• Orange/yellow fruits

Adding dietary fat improves absorption of carotenoids.

Why Excess Supplementation Is Not Harmless

Vitamin A is fat-soluble and can accumulate.

Chronic excess may cause:

• Hepatotoxicity
• Bone abnormalities
• Intracranial hypertension
• Teratogenicity

Therefore long-term high-dose supplementation should follow:

Established clinical or public-health guidance.

Major Ocular Complications

Untreated severe VAD may lead to:

• Corneal ulceration
• Keratomalacia
• Secondary microbial keratitis
• Corneal perforation
• Dense corneal scar
• Phthisis
• Permanent blindness

In children, persistent unilateral or asymmetric opacity can also produce:

Amblyopia.

Expected Prognosis

Prognosis is excellent when deficiency is recognized:

Before destructive corneal disease develops.

Night blindness and early epithelial abnormalities are highly reversible.

Prognosis becomes much worse once there is:

• Deep stromal melting
• Perforation
• Dense central scarring
• Secondary infection

High-Yield Takeaways

• Xerophthalmia is the ocular manifestation of vitamin A deficiency and ranges from night blindness to keratomalacia and blindness.
• The earliest classic symptom is night blindness because vitamin A is required for rhodopsin regeneration in rod photoreceptors.
• Vitamin A also maintains conjunctival and corneal epithelial differentiation and goblet-cell function.
• The WHO sequence is XN → X1A → X1B → X2 → X3A/X3B → XS, representing progressively more severe disease.
• Bitot spots are foamy white keratinized plaques, usually on the temporal bulbar conjunctiva.
• Keratomalacia is a medical and ophthalmic emergency because corneal melting and perforation can progress rapidly.
• Important risk factors include malnutrition, malabsorption, bariatric surgery, liver/pancreatic disease, severe dietary restriction, and childhood measles.
• Serum retinol <0.70 µmol/L supports deficiency, but levels can be depressed by systemic inflammation and protein deficiency.
• Schirmer testing is not the key diagnostic test; xerophthalmia is fundamentally a nutritional epithelial disease rather than ordinary dry eye.
• Treatment requires urgent systemic vitamin A, not lubrication alone.
• A commonly used WHO regimen for patients ≥12 months is 200,000 IU orally immediately, the next day, and again approximately 2 weeks later, with lower age-adjusted doses for younger infants.
• Severe malabsorption may require parenteral replacement.
• Pregnancy requires specialist-guided dosing because excessive preformed vitamin A can be teratogenic.
• Topical retinoic acid and punctal plugs are not routine primary treatments for xerophthalmia.
• Advanced corneal disease requires aggressive surface protection and treatment of secondary infection while the systemic deficiency is corrected.
• Nutritional rehabilitation must also address protein deficiency, zinc deficiency, infection, and the underlying cause of malabsorption.
• Early disease can reverse rapidly, but established corneal scarring produces permanent visual loss.
• Population prevention relies on dietary diversification, food fortification, supplementation programs, measles vaccination, and improved nutrition and sanitation.

Ophthalmology – Uveitis-Glaucoma-Hyphema Syndrome

What the Syndrome Represents

Uveitis-glaucoma-hyphema (UGH) syndrome is a secondary inflammatory and hemorrhagic glaucoma caused by repetitive mechanical contact between an intraocular lens (IOL) or its haptics and adjacent uveal tissue.

The classic triad is:

• Anterior uveitis
• Elevated intraocular pressure
• Hyphema or microhyphema

The central mechanism is:

IOL-related chafing of the iris or ciliary body → pigment and blood release → inflammation → trabecular obstruction → raised IOP.

Why the Syndrome Has Changed With Modern Cataract Surgery

Historically, UGH was most strongly associated with:

• Iris-supported lenses
• Closed-loop anterior chamber IOLs

These lenses are now rarely used.

Modern UGH more often results from:

• Malpositioned posterior chamber IOLs
• Sulcus placement of an inappropriate IOL
• Subluxated IOL-bag complexes
• Haptic contact with the posterior iris
• Capsular-bag instability

Therefore UGH should not be considered exclusively a complication of old anterior chamber lenses.

Which IOL Situations Carry the Greatest Risk

Important mechanical settings include:

• Posterior chamber IOL haptic in the sulcus
• Single-piece acrylic IOL inadvertently positioned in the ciliary sulcus
• Tilted IOL
• Decentered IOL
• Subluxated capsular bag–IOL complex
• Iris-fixated IOL
• Malpositioned anterior chamber IOL
• Broken or displaced haptic

Why Single-Piece Acrylic IOLs Are Problematic in the Sulcus

Single-piece acrylic lenses generally have:

• Thick haptics
• Square-edged optics
• Relatively bulky design

If placed in the sulcus, they can repeatedly rub against the posterior iris and produce:

• Pigment dispersion
• Iris transillumination
• Chronic inflammation
• Recurrent microhyphema
• Elevated IOP

This is an important modern cause of UGH.

In-the-Bag UGH

UGH can even occur when the IOL is technically:

Inside the capsular bag.

Possible mechanisms include:

• Zonular weakness
• Pseudoexfoliation
• Capsular contraction
• Bag-IOL complex subluxation
• Soemmering ring formation
• Progressive IOL tilt

These changes can bring the lens or haptic into contact with the iris or ciliary body.

Why Pseudoexfoliation Matters

Pseudoexfoliation predisposes to:

• Zonular weakness
• Delayed IOL-bag complex instability
• Lens decentration
• Subluxation

This can create delayed-onset UGH many years after apparently uncomplicated cataract surgery.

When UGH Can Appear

Symptoms may begin:

• Soon after cataract surgery
• Months later
• Years or even decades after implantation

Delayed presentation is particularly common when the cause is:

• Progressive zonular failure
• Capsular contraction
• Late IOL subluxation

What Patients Usually Notice

Symptoms may be intermittent.

Common complaints include:

• Episodes of blurred vision
• Ocular redness
• Ache or discomfort
• Photophobia
• Halos
• Transient reduction in vision

Some patients notice symptoms after:

• Exercise
• Eye rubbing
• Certain head positions

because these may increase IOL-iris contact.

Why Vision May Fluctuate

Transient blur may result from:

• Microhyphema
• Anterior chamber inflammation
• IOP elevation
• Corneal edema
• IOL decentration

Blood may settle rapidly, so the eye can appear relatively quiet between attacks.

The Classic Examination Pattern

Typical findings include:

• Anterior chamber cells
• Pigment
• Elevated IOP
• Microhyphema or frank hyphema
• Iris transillumination defects
• IOL decentration or tilt
• Pigment on the IOL

Not every patient demonstrates the complete triad at every visit.

Microhyphema Can Be Easy to Miss

A patient may have only:

• A few circulating erythrocytes
• Inferior red blood cells
• No visible layered hyphema

Careful slit-lamp examination may therefore be necessary to detect:

Recurrent microbleeding.

Iris Transillumination Defects

Repeated haptic or optic contact can abrade the posterior iris pigment epithelium.

This produces:

• Focal or arcuate iris transillumination defects
• Pigment dispersion
• Pigment on the lens surface

The location of the defect may help identify the site of mechanical contact.

Gonioscopy

Gonioscopy is useful for detecting:

• Blood in the angle
• Heavy trabecular pigmentation
• Peripheral anterior synechiae
• Iris or angle neovascularization
• A malpositioned haptic in selected cases

It is particularly important for excluding:

Neovascular glaucoma.

Why UBM Is So Useful

Ultrasound biomicroscopy (UBM) is one of the most valuable tests when the offending IOL-haptic relationship cannot be seen directly.

It can demonstrate:

• Haptic-iris contact
• Haptic-ciliary body contact
• IOL tilt
• Sulcus malposition
• Capsular bag displacement
• Zonular abnormalities

Anterior Segment OCT

Anterior segment OCT may also help evaluate:

• IOL position
• Iris configuration
• Anterior haptic relationships

However, UBM is often superior for structures located:

Behind the iris.

Why the Optic Nerve Must Also Be Evaluated

Repeated or sustained IOP elevation may produce:

Secondary glaucomatous optic neuropathy.

Evaluation should therefore include:

• Optic disc examination
• RNFL OCT
• Macular ganglion cell analysis
• Automated visual fields

Other Retinal Complications

UGH may be associated with:

• Cystoid macular edema
• Vitreous hemorrhage
• Epiretinal membrane in chronic inflammation

The term UGH-plus syndrome is sometimes used when posterior segment complications such as vitreous hemorrhage or CME are present.

OCT of the Macula

Macular OCT is useful when visual loss is greater than expected from:

• IOP
• Hyphema
• IOL position

It can identify:

Cystoid macular edema, a recognized complication of chronic IOL irritation.

Important Diagnostic Alternatives

Recurrent inflammation, hyphema, and elevated IOP in a pseudophakic eye can also result from:

• Neovascular glaucoma
• Uveitic glaucoma
• Retained lens material
• Chronic postoperative endophthalmitis
• Pigment dispersion from another mechanism
• Ghost-cell glaucoma
• Trauma
• Iris or ciliary body tumor
• Carotid-cavernous fistula
• Swan syndrome

Why Neovascular Glaucoma Must Be Excluded

Neovascular glaucoma can produce:

• Elevated IOP
• Hyphema
• Anterior inflammation

Look carefully for:

• Neovascularization of the iris
• Neovascularization of the angle
• Retinal ischemic disease

The underlying management is completely different from UGH.

Swan Syndrome

Swan syndrome refers to recurrent hyphema arising from abnormal vessels at a previous surgical wound.

It may also produce elevated IOP.

Unlike UGH, the bleeding source is typically:

Vascularization at the corneoscleral wound, rather than IOL chafing.

Chronic Postoperative Endophthalmitis

Low-grade infection after cataract surgery may cause:

• Persistent or recurrent anterior uveitis
• Reduced vision
• Sometimes elevated IOP

Clues include:

• Capsular plaque
• Chronic inflammation not clearly related to mechanical contact

This must be considered before attributing recurrent inflammation solely to UGH.

First Management Goal

The initial objectives are:

1. Control inflammation
2. Lower IOP
3. Control hyphema
4. Identify the mechanical cause

Medical therapy is usually:

Temporizing rather than definitive.

Treating the Inflammation

Topical corticosteroids such as:

Prednisolone acetate

can suppress anterior segment inflammation.

The dose depends on:

• Degree of uveitis
• Corneal status
• IOP

Prolonged steroid therapy without correcting the mechanical problem is usually inadequate.

Role of Cycloplegia

Cycloplegic agents may be used when there is:

• Painful anterior uveitis
• Posterior synechiae
• Significant ciliary spasm

Examples include:

• Cyclopentolate
• Atropine in more severe cases

Routine atropine is not necessary in every UGH presentation.

Lowering the IOP

Aqueous suppressants are commonly used first:

• Beta-blocker
• Topical carbonic anhydrase inhibitor
• Alpha-2 agonist

Systemic acetazolamide can be added for:

More substantial pressure elevation.

Prostaglandin Analogues

Prostaglandin analogues may also lower IOP effectively.

During marked active inflammation or CME, many clinicians initially favor other agents, but prostaglandins are:

Not absolutely contraindicated.

They may be useful in chronic pressure management when appropriate.

Hyperosmotic Therapy

For severe acute IOP elevation, hyperosmotic therapy such as:

IV mannitol

may occasionally be required.

This is reserved for significant pressure elevation rather than routine UGH.

Managing the Hyphema

Management may include:

• Activity limitation
• Head elevation
• Control of inflammation
• Control of IOP

Large or persistent hyphema may occasionally require:

Anterior chamber washout.

Anticoagulants and Antiplatelet Drugs

Anticoagulation can increase the severity or persistence of bleeding from mechanically traumatized iris vessels.

However:

Do not discontinue medically necessary anticoagulant or antiplatelet therapy solely because of UGH without coordination with the prescribing physician.

If anticoagulation is excessive, appropriate laboratory assessment may be indicated.

Why Medical Therapy Often Fails Long Term

Steroids and glaucoma drops treat the:

Consequences

of UGH.

They do not eliminate:

Mechanical IOL-uveal contact.

If rubbing continues, inflammation and hemorrhage tend to recur.

Definitive Treatment

The definitive treatment is:

Elimination of the offending IOL-iris or IOL-ciliary body contact.

This may require:

• IOL repositioning
• Haptic repositioning
• IOL exchange
• Removal of the IOL
• Capsular bag stabilization in selected cases

IOL Repositioning

Repositioning may be appropriate when:

• The existing IOL is suitable
• Malposition can be reliably corrected
• Capsular or zonular support is adequate

Possible strategies include:

• Repositioning into the capsular bag
• Scleral fixation
• Iris fixation in selected anatomy

IOL Exchange

Exchange is favored when:

• The IOL design is inappropriate for its location
• A single-piece acrylic lens is in the sulcus
• Haptic damage is present
• Repositioning cannot reliably eliminate contact

Replacement options depend on remaining support.

What Can Replace the Offending Lens

Depending on anatomy, options may include:

• Posterior chamber IOL in the bag
• Three-piece sulcus IOL
• Scleral-fixated posterior chamber IOL
• Iris-fixated lens
• Selected modern anterior chamber IOL

Choice is individualized.

Role of Anterior Chamber Washout

Washout may be indicated for:

• Persistent significant hyphema
• Uncontrolled IOP from blood
• Corneal blood staining risk
• Simultaneous IOL revision

It does not provide definitive treatment if the mechanical source remains.

Is Laser Ablation Still Important?

Older reports described argon laser ablation of isolated bleeding vessels.

This is now:

An uncommon and highly selected treatment.

Modern management usually focuses on correcting the underlying mechanical IOL problem rather than repeatedly treating secondary bleeding vessels.

What If Glaucoma Persists After IOL Correction?

Some eyes develop permanent trabecular damage from:

• Chronic pigment deposition
• Repeated hemorrhage
• Longstanding inflammation

IOP may therefore remain elevated even after mechanical correction.

These patients may need:

• Glaucoma medications
• Laser in selected anatomy
• Trabeculectomy
• Glaucoma drainage device
• Other glaucoma procedures

Why the Mechanical Cause Should Usually Be Corrected First

When feasible, correcting the IOL problem before glaucoma surgery is logical because:

Continued iris chafing can perpetuate inflammation, bleeding, and surgical failure.

Glaucoma surgery is then reserved for persistent pressure elevation.

Follow-Up During Active Disease

Initial follow-up depends on:

• IOP
• Amount of hyphema
• Severity of inflammation
• Corneal edema
• Optic nerve status

Significant pressure elevation may require:

Review within hours to days.

Long-Term Monitoring

After treatment, monitor:

• IOP
• Anterior chamber inflammation
• Recurrent hyphema
• IOL position
• Optic nerve
• Visual fields
• Macular OCT when indicated

Recurrence suggests persistent:

Mechanical contact or renewed IOL instability.

Expected Outcome

Prognosis is generally good when UGH is:

• Recognized early
• Correctly attributed to IOL contact
• Definitively treated before substantial optic nerve damage occurs

Visual outcome is worse when there is:

• Advanced glaucoma
• Chronic CME
• Corneal damage
• Recurrent vitreous hemorrhage
• Delayed diagnosis

Major Complications

Potential complications include:

• Secondary glaucoma
• Permanent glaucomatous visual-field loss
• Recurrent hyphema
• Chronic anterior uveitis
• Cystoid macular edema
• Vitreous hemorrhage
• Corneal edema
• Progressive visual impairment

High-Yield Takeaways

• UGH syndrome is caused by mechanical chafing of the iris or ciliary body by an IOL or its haptics, producing uveitis, hyphema, and elevated IOP.
• The entire triad does not need to be present simultaneously; recurrent microhyphema or pigment dispersion may be the only clue at a particular visit.
• Historically associated with old anterior chamber lenses, modern UGH more often occurs with malpositioned, subluxated, or incorrectly positioned posterior chamber IOLs.
• A single-piece acrylic IOL in the ciliary sulcus is a particularly important modern cause because its thick haptics and square optic edge can chronically abrade the posterior iris.
• UGH can occur even with an in-the-bag IOL, especially when pseudoexfoliation, zonular weakness, capsular contraction, or late bag-IOL subluxation develops.
• Examination may reveal microhyphema, anterior chamber cells, pigment, iris transillumination defects, and elevated IOP.
• Gonioscopy helps identify angle blood, pigmentation, haptic abnormalities, and—critically—exclude iris or angle neovascularization.
• Ultrasound biomicroscopy is especially valuable for demonstrating hidden haptic-iris or haptic-ciliary body contact.
• Macular OCT should be considered because chronic UGH may produce cystoid macular edema.
• Initial treatment consists of topical corticosteroids, appropriate cycloplegia, and IOP-lowering therapy, but this is usually temporary.
• Anticoagulants can worsen bleeding but should not be stopped automatically without considering the systemic indication.
• The definitive treatment is removal of the mechanical cause, usually by IOL repositioning or exchange.
• Argon laser treatment of bleeding vessels is now a rarely used selected intervention, not the usual definitive strategy.
• If glaucoma persists after IOL correction, chronic trabecular damage may require long-term medications or glaucoma surgery.
• In any pseudophakic patient with recurrent unexplained iritis, hyphema, pigment dispersion, or unilateral elevated IOP, carefully reassess the IOL position and its relationship to the iris and ciliary body.

Ophthalmology – Tuberous Sclerosis Complex

What the Disorder Represents

Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem genetic disorder characterized by development of:

• Hamartomas
• Benign tumors
• Dysplastic lesions

in multiple organs, especially:

• Brain
• Skin
• Kidneys
• Heart
• Lungs
• Retina

It results from pathogenic variants affecting the:

TSC1–TSC2–mTOR signaling pathway.

⸻

Important Modern Terminology

The preferred name is:

Tuberous sclerosis complex

rather than simply “tuberous sclerosis.”

The historic triad of:

• Seizures
• “Adenoma sebaceum”
• Intellectual disability

is known as the Vogt triad, but it is:

Neither sensitive nor required for diagnosis.

Many patients do not have all three findings.

⸻

Important Modern Correction About Language

Older descriptions used:

• “Adenoma sebaceum”
• “Mental retardation”

Modern terminology is:

• Facial angiofibromas
• Intellectual disability

Facial angiofibromas are neither adenomas nor sebaceous lesions.

⸻

Genetic Basis

TSC results from pathogenic variants in:

• TSC1 on chromosome 9 → encodes hamartin
• TSC2 on chromosome 16 → encodes tuberin

Hamartin and tuberin form a complex that normally suppresses:

mTORC1 signaling.

Loss of this inhibitory pathway produces excessive:

• Cell growth
• Protein synthesis
• Proliferation
• Hamartoma formation

⸻

Why mTOR Is So Important

The central molecular abnormality is:

Overactivation of the mechanistic target of rapamycin pathway.

This explains why:

mTOR inhibitors such as everolimus and sirolimus

now have established therapeutic roles in TSC.

⸻

Inheritance Pattern

TSC is:

Autosomal dominant

with variable expression.

However, a large proportion of affected individuals represent:

De novo pathogenic variants

and therefore have no affected parent.

⸻

Genetic Testing – Major Modern Correction

Older sources stated that reliable genetic testing was unavailable.

This is now incorrect.

Modern molecular testing can identify a pathogenic variant in:

TSC1 or TSC2 in most patients with clinically definite TSC.

Genetic testing is useful for:

• Confirming diagnosis
• Family counseling
• Testing at-risk relatives
• Prenatal or reproductive counseling

A negative genetic test does not completely exclude TSC because mosaic or difficult-to-detect variants can occur.

⸻

Who Develops It

TSC occurs in all ethnic groups and both sexes.

Estimated birth incidence is roughly:

1 in 6,000–10,000 live births

although prevalence estimates vary.

Clinical severity ranges from:

• Very mild disease discovered incidentally
• Severe neurologic, renal, pulmonary, or developmental disease

⸻

Why the Phenotype Is So Variable

Even individuals within the same family may have very different manifestations.

Variation results from:

• Different pathogenic variants
• Mosaicism
• Second-hit somatic mutations
• Other genetic and environmental modifiers

Therefore genotype does not perfectly predict clinical severity.

⸻

Major Organ Systems Involved

TSC most commonly affects:

• Central nervous system
• Skin
• Kidneys
• Heart
• Lungs
• Retina
• Teeth/oral cavity
• Bone

It is therefore fundamentally a:

Multidisciplinary disease.

⸻

Neurologic Manifestations

Major neurologic abnormalities include:

• Cortical tubers
• Subependymal nodules
• Subependymal giant cell astrocytoma
• Epilepsy
• Infantile spasms
• Neurodevelopmental disorders

Seizures are among the most common and clinically important manifestations.

⸻

Cortical Tubers

Cortical and subcortical tubers are areas of:

• Abnormal cortical development
• Dysplastic neurons
• Giant cells
• Gliosis

They are strongly associated with:

Epilepsy and neurodevelopmental impairment.

⸻

Subependymal Nodules

Subependymal nodules occur along the walls of the lateral ventricles.

They may:

• Calcify
• Remain stable
• Occasionally evolve into or coexist with a subependymal giant cell astrocytoma (SEGA)

⸻

Subependymal Giant Cell Astrocytoma

SEGA typically develops near the:

Foramen of Monro

and can obstruct cerebrospinal fluid flow.

Potential consequences include:

• Hydrocephalus
• Headache
• Vomiting
• Papilledema
• Behavioral change
• Reduced consciousness

⸻

Ocular Relevance of Raised Intracranial Pressure

A patient with TSC and SEGA may develop:

Papilledema

if obstructive hydrocephalus occurs.

Papilledema in TSC is therefore usually a consequence of intracranial pressure, not a primary retinal manifestation.

⸻

Infantile Spasms

Infantile spasms are particularly important in TSC.

They may present with:

• Brief flexor spasms
• Extensor spasms
• Head nodding
• Clusters of repetitive movements

They require:

Prompt neurologic treatment.

⸻

First-Line Treatment of Infantile Spasms

In TSC-associated infantile spasms:

Vigabatrin is generally first-line therapy.

This is a major modern management point.

⸻

Ophthalmic Relevance of Vigabatrin

Vigabatrin can cause:

Permanent concentric visual-field loss

through retinal toxicity.

Risk relates particularly to:

• Cumulative exposure
• Duration of therapy

Children receiving vigabatrin require age-appropriate ophthalmic monitoring when feasible.

⸻

TSC-Associated Neuropsychiatric Disorders

The umbrella term:

TAND – TSC-associated neuropsychiatric disorders

includes:

• Intellectual disability
• Autism spectrum disorder
• ADHD
• Anxiety
• Mood disorders
• Behavioral difficulties
• Sleep problems
• Learning disorders

These manifestations are common but highly variable.

⸻

Characteristic Skin Findings

Cutaneous findings are often important diagnostic clues.

They include:

• Hypomelanotic macules
• Facial angiofibromas
• Shagreen patch
• Ungual/periungual fibromas
• Confetti skin lesions

⸻

Hypomelanotic Macules

These are often called:

Ash-leaf macules

because of their shape.

They may be present:

At birth or early infancy

and are often easier to detect with:

Wood lamp examination.

⸻

Facial Angiofibromas

Facial angiofibromas are:

• Reddish papules
• Frequently distributed over the nose and central face
• Often appearing during childhood

They were historically called:

Adenoma sebaceum, an outdated term.

⸻

Shagreen Patch

A shagreen patch is:

• Thickened
• Leathery
• Connective-tissue nevus-like plaque

often located over the:

Lumbosacral region.

⸻

Ungual Fibromas

Periungual or subungual fibromas:

• Develop around nails
• Are more common later in childhood or adulthood

These are also called:

Koenen tumors.

⸻

Major Ocular Manifestation

The classic eye lesion in TSC is:

Retinal astrocytic hamartoma.

These lesions may occur:

• On the optic disc
• Adjacent to the disc
• In the peripheral retina

They can be:

• Solitary
• Multiple
• Unilateral
• Bilateral

Multiple bilateral lesions strongly support TSC.

⸻

Retinal Astrocytic Hamartoma – Clinical Appearance

These lesions may appear as:

• Flat translucent retinal thickening
• Gray-white nodules
• Calcified “mulberry-like” masses

They often arise from the:

Retinal nerve fiber layer.

⸻

Traditional Morphologic Patterns

Three classic appearances are described:

Type 1

Relatively flat, smooth, semitranslucent lesion.

Type 2

Calcified, nodular:

“Mulberry” lesion

Type 3

Mixed characteristics.

These patterns may represent stages along a morphologic spectrum.

⸻

Optic Disc Involvement

Astrocytic hamartomas may arise:

• On the optic nerve head
• Immediately adjacent to it

They can resemble:

• Optic disc drusen
• Papilledema
• Other calcified lesions

Multimodal imaging helps clarify the diagnosis.

⸻

Optical Coherence Tomography

OCT may demonstrate:

• Hyperreflective retinal mass
• Distortion of retinal layers
• Calcification-related shadowing
• Intraretinal cystic change in exudative lesions

OCT is useful for:

• Baseline documentation
• Monitoring growth
• Detecting associated fluid

⸻

Fundus Autofluorescence

Calcified astrocytic hamartomas may demonstrate:

Hyperautofluorescence

although appearance varies according to:

• Calcification
• Pigment
• Overlying retina

⸻

B-Scan Ultrasonography

Larger calcified lesions may show:

• High internal reflectivity
• Acoustic shadowing

This can help distinguish heavily calcified hamartomas from other retinal masses.

⸻

Fluorescein Angiography

FA may show:

• Intrinsic tumor vasculature
• Late staining
• Leakage in more active or exudative lesions

Routine FA is unnecessary for asymptomatic stable lesions.

⸻

Retinal Hypopigmented Lesions

Some patients have:

Retinal achromic patches

which appear as hypopigmented retinal or RPE lesions.

These are recognized as a:

Minor diagnostic feature in modern criteria.

⸻

Are Retinal Hamartomas Usually Dangerous?

Most retinal astrocytic hamartomas are:

Stable and asymptomatic.

They often require:

Observation only.

⸻

Rare Ocular Complications

Occasionally, retinal astrocytic hamartomas may produce:

• Exudation
• Macular edema
• Serous retinal detachment
• Vitreous hemorrhage
• Retinal neovascularization
• Fibrosis
• Secondary glaucoma

Severe progressive ocular disease is uncommon.

⸻

Can Retinal Hamartomas Grow?

Yes, but substantial progression is uncommon.

Some lesions may:

• Slowly enlarge
• Become more calcified
• Develop exudation

Serial photography and OCT are useful when growth is uncertain.

⸻

Differential Diagnosis of Retinal Astrocytic Hamartoma

Important mimics include:

• Retinoblastoma
• Optic disc drusen
• Solitary retinal astrocytic hamartoma
• Myelinated retinal nerve fibers
• Toxocariasis
• Coats disease
• Other calcified retinal lesions

⸻

Distinguishing It From Retinoblastoma

This is particularly important in young children.

Retinoblastoma more commonly shows:

• True intraocular tumor mass
• Prominent calcification
• Subretinal or vitreous seeds
• Progressive growth
• Retinal detachment

TSC-associated astrocytic hamartomas are usually:

• Surface retinal lesions
• Relatively stable
• Often multiple or bilateral
• Associated with other TSC features

⸻

Solitary Retinal Astrocytic Hamartoma

An isolated retinal astrocytic hamartoma may occur in a patient without TSC.

Therefore:

One retinal astrocytic hamartoma does not automatically diagnose tuberous sclerosis complex.

The systemic context matters.

⸻

Cardiac Manifestations

The classic cardiac lesion is:

Rhabdomyoma.

These are often detected:

• Prenatally
• During infancy

They may cause:

• Arrhythmia
• Obstruction
• Heart failure

Many regress spontaneously during childhood.

⸻

Why Cardiac Rhabdomyoma Is a Diagnostic Clue

Multiple fetal or neonatal cardiac rhabdomyomas are strongly associated with:

TSC

and may prompt genetic evaluation before other manifestations become apparent.

⸻

Renal Manifestations

Major renal abnormalities include:

• Angiomyolipomas
• Renal cysts
• Chronic kidney disease

Rarely:

• Renal cell carcinoma

Renal disease is a major determinant of long-term morbidity.

⸻

Renal Angiomyolipoma

Angiomyolipomas consist of varying proportions of:

• Blood vessels
• Smooth muscle
• Fat

Large lesions may cause:

• Hemorrhage
• Flank pain
• Hematuria
• Renal impairment

⸻

Modern Treatment of Renal Angiomyolipoma

For enlarging or clinically significant TSC-associated angiomyolipoma:

mTOR inhibition with everolimus

is now an established treatment option.

Selective embolization is preferred for:

Acute hemorrhage.

Nephron-sparing approaches are favored whenever possible.

⸻

Pulmonary Manifestations

The major pulmonary complication is:

Lymphangioleiomyomatosis (LAM).

It occurs predominantly in:

Women after puberty.

⸻

Lymphangioleiomyomatosis

LAM produces abnormal proliferation of smooth-muscle-like cells leading to:

• Pulmonary cysts
• Dyspnea
• Pneumothorax
• Chylous effusion
• Progressive loss of lung function

Chest CT is much more sensitive than chest radiography.

⸻

Modern Treatment of LAM

Clinically significant LAM may be treated with:

Sirolimus

which can stabilize or improve pulmonary function.

Lung transplantation is reserved for severe end-stage disease.

⸻

Oral Findings

Oral manifestations may include:

• Dental enamel pits
• Gingival fibromas

These can support the diagnosis.

⸻

Bone Findings

Sclerotic bone lesions may occur, particularly in:

• Spine
• Pelvis
• Skull

They are often asymptomatic and usually do not require treatment.

⸻

Modern Diagnostic Framework

TSC is diagnosed using:

• Clinical criteria
• Molecular genetic criteria

A pathogenic variant in:

TSC1 or TSC2

can establish a molecular diagnosis.

⸻

Definite Clinical Diagnosis

A definite clinical diagnosis generally requires:

Two major features

or:

One major feature plus at least two minor features.

This basic structure remains clinically useful.

⸻

Major Diagnostic Features

Major features include:

• ≥3 hypomelanotic macules
• ≥3 facial angiofibromas or fibrous cephalic plaque
• ≥2 ungual fibromas
• Shagreen patch
• Multiple retinal hamartomas
• Cortical dysplasias
• ≥2 subependymal nodules
• SEGA
• Cardiac rhabdomyoma
• LAM
• ≥2 renal angiomyolipomas

⸻

Minor Diagnostic Features

Minor features include:

• Confetti skin lesions
• 3 dental enamel pits
• ≥2 intraoral fibromas
• Retinal achromic patch
• Multiple renal cysts
• Nonrenal hamartomas
• Selected sclerotic bone lesions

Criteria have evolved over time, so older “probable” and “suspect” categories should not be relied on without reference to current consensus definitions.

⸻